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Abstract
Protein phosphorylation is controlled by protein kinases, and represents a critical
signaling mechanism involved in the regulation of fundamental biological processes.
Furthermore, the aberrant regulation of kinase activity is implicated in diseases such as
cancer and has resulted in efforts to target kinases therapeutically. Protein kinase CK2,
although frequently considered constitutively active, has emerged as a clinical target on the
basis of its altered expression in different types of human cancers and its regulatory
participation in multiple biological processes. In fact, CX-4945, a small molecule ATPcompetitive inhibitor of CK2 has advanced to clinical trial and has been widely used to
interrogate CK2-dependent signaling events in cells. Despite its widespread applications, an
understanding of the mechanism of action of CX-4945 on cells remains limited.
In this thesis, comparison of proteomic sample preparation strategies led to the
development of a phosphoproteomic workflow that enabled the enrichment of
phosphopeptides conforming to the CK2 consensus sequence. Using the optimized workflow,
phosphoproteomic profiling was conducted in HeLa cells treated with CX-4945. Several
phosphorylation sites conforming to the recognition motif for CK2 phosphorylation
displayed significantly decreased phosphorylation in response to CX-4945. Kinase substrate
enrichment analysis also revealed a broad impact of CX-4945 on several kinases other than
CK2. Profiling of the kinome utilizing multiplexed inhibitor beads also revealed changes in
the activity of other kinases including activation of the ERK MAPK pathway and inhibition
of the PI3K/Akt/mTOR pathway. Studies with Inhibitor VIII, an unrelated CK2 inhibitor,
also resulted in activation of the ERK MAPK pathway suggesting that CK2 has a role in
regulating this pathway. By comparison, the PI3K/Akt/mTOR pathway was not affected by
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Inhibitor VIII indicating that the effects of CX-4945 on that pathway are independent of
CK2.
Overall, this investigation provides valuable insight into the regulation of the
phosphoproteome and the kinome in response to CX-4945 in HeLa cells. Dynamic markers
of CK2 activity in cells were identified and putative CK2-independent effects of CX-4945
were revealed.

Collectively, these studies illustrate the utility of global proteomic

approaches to elucidate the cellular effects of clinical-stage kinase inhibitors.
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1.1

Chapter 1 – Introduction
General Introduction1

The reversible phosphorylation of cellular proteins that is catalyzed by protein kinases
represents a central mechanism for the transmission of intracellular signals (1). In eukaryotes,
protein kinases catalyze the transfer of phosphate from ATP to the hydroxyl group located on
side chains of amino acids serine, threonine and tyrosine. The phosphate group can be
removed by a specific phosphatase when no longer required (2). Phosphorylation plays a
pivotal regulatory role in a broad array of cellular responses including activation of
transcription factors (3), conformational change in protein structure (4), and the mediation of
protein-protein interactions which comprise signal transduction pathways (5). Approximately
700,000 potential phosphorylation sites could exist in the human proteome (6), with nearly
three quarters of proteins that are detectable by mass spectrometry being phosphorylated,
demonstrating the widespread impact of phosphorylation in maintaining cellular processes
(7). Not surprisingly, because of the critical role in regulatory signaling pathways, the
deregulation of kinases can lead to pathophysiological processes such as cancer (8) and has
prompted interest in kinases as drug targets for cancer therapeutics (9).
1.2

Protein Kinase CK2
Protein kinase CK2 represents one small protein kinase family that has recently

emerged as a potential therapeutic target based on alterations in its expression or activity in a
number of cancers (10). CK2 is composed of two closely related catalytic isoforms CK2α
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Excerpts of this chapter are reproduced with permission from:
Rabalski, A. J., Gyenis, L., and Litchfield, D. W. (2016) Molecular Pathways: Emergence of
Protein Kinase CK2 (CSNK2) as a Potential Target to Inhibit Survival and DNA Damage
Response and Repair Pathways in Cancer Cells. Clin. Cancer Res. 22, 2840–2847
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and CK2α’ (encoded by CSNK2Α1 and CSNK2A2 genes respectively) that both display
catalytic activity in the presence or absence of its regulatory CK2β (CSNK2Β) subunit. The
regulatory CK2β subunit is not essential for activity, but can impact the ability of the
catalytic subunits to phosphorylate certain substrates (11). CK2 has also been shown to be
essential for viability, as deletion of CK2α or CK2β leads to embryonic lethality in mice (12,
13). A recent analysis of transcript expression profiles for CSNK2A1, CSNK2A2 and
CSNK2B in neoplastic tissues versus normal tissues deposited in the Oncomine database
revealed varying degrees of altered expression of individual CK2 subunits suggesting that
deregulation of CK2 subunit expression profiles promotes cancer (14). To this point, the
CK2-dependent phosphoproteome has not yet been fully elucidated and the impact of
alterations in CK2 on the phosphoproteome has not yet been systematically investigated.
Nevertheless, it is evident both from an extensive literature and computational predictions of
its substrates based on its consensus recognition motif (S/T-X-X-D/E/pS/pY) that CK2 could
be implicated in a vast landscape of biological processes (Figure 1.1) with >2000 putative
phosphorylation sites in the human proteome (15). While more comprehensive discussions of
CK2 can be found elsewhere (16, 17), we will highlight the involvement of CK2 in specific
cellular processes, including its convergence with caspase pathways and its roles in DNA
response and repair pathways, which have inspired ongoing efforts to exploit CK2 as a
therapeutic target.

3

Figure 1.1 Protein Kinase CK2 is Implicated in Different Biological Processes
CK2 (referred to as CSNK2 in the figure) is presented with examples of putative substrates
or interacting proteins involved in each biological process listed. These proteins were
identified using gene ontology biological processes according to the following databases:
UniProt, Reactome, PHOSIDA and PubMed. This figure is reproduced with permission from
AACR.
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1.3

Convergence of CK2 with Caspase Pathways

CK2 is generally considered to be a constitutively active enzyme (ie. its catalytic subunits do
not require activating phosphorylation, association with its regulatory subunit or the presence
of second messengers to be catalytically active), which is expressed at higher levels in many
forms of human cancer (14, 18-20). These observations are particularly intriguing when
considering the remarkable resemblance of the consensus recognition motif of CK2 with that
of caspases (Figure 1.2 A) which cleave substrates at aspartic acid residues during the
progression of apoptosis. In fact, several published examples (Figure 1.2 A) demonstrate that
caspase substrates, including Bid which promotes apoptotic progression when it is cleaved,
can be phosphorylated by CK2 at sites adjacent to caspase cleavage sites.

Since

phosphorylation adjacent to caspase cleavage sites blocks cleavage, these observations
suggest that increased phosphorylation by CK2 could promote cell survival by inhibiting
caspase action (21-26).
Building on these observations, a combined computational and biochemical approach
revealed an extensive repertoire of proteins with overlapping CK2 and caspase recognition
motifs suggesting that CK2 could have widespread impact on caspase action (27).

In

addition to the identification of many proteins known to be caspase substrates, these studies
also demonstrated that CK2 could phosphorylate caspase-3 to prevent its cleavage by
upstream caspases activated by intrinsic and extrinsic apoptotic stimuli (Figure 1.2 A).
Collectively, these findings demonstrate that CK2 has the potential to inhibit caspase action
at both the level of caspase activation and cleavage of downstream substrates. Furthermore,
these findings raise the prospect that the higher (ie. pathological) levels of CK2 that are
observed in cancer cells could result in the pathological rewiring of caspase pathways to
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promote cell survival. Interestingly, further characterization of the relationship between CK2
and caspases revealed intriguing isoform specificity. In this respect, caspase-3 appears to be
preferentially phosphorylated by CK2α’ rather than CK2α despite the fact that these two
isoforms of CK2 have very similar enzymatic characteristics (33). Furthermore, CK2β
attenuated phosphorylation suggesting that misregulation of CK2 subunits in cells could be
an additional mechanism to affect the regulation of apoptosis (24). The capacity of CK2 to
promote cancer cell survival in vitro was also revealed in a recent large scale screen utilizing
RNAi knockdown and cDNA overexpression of kinases in DLD-1 colorectal
adenocarconima cells where overexpression of CK2α promoted resistance to TRAIL as
determined by flow-cytometry utilizing antibodies against cleaved PARP and cleaved
caspase-3 (34). Overall, while CK2 is only one of many constituents that intersect caspase
pathways, its ability to modulate caspase action through phosphorylation of caspase
substrates (potentially including caspases themselves) represents one potential mechanism by
which CK2 might be exploited to neutralize cancer cell survival.
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Figure 1.2 CK2 in the Control of Cell Survival and Response to DNA Damage
A) On the basis of the remarkable similarity of the consensus recognition motifs for
phosphorylation by CK2 (S/T-D-X-X-D/E) and cleavage by caspases (E-X-D), it is evident
that there are many cellular proteins where CSNK2 phosphorylation could occur adjacent to
caspase cleavage sites to block their cleavage by caspases (27). B) Proteins shown here are
involved in DNA damage repair, which requires phosphorylation by CK2 to execute
respective DNA repair processes. A recurring theme with the illustrated proteins (i.e.,
MDC1, RAD51, and TCOF1) is the ability of CK2 to promote phosphorylation-dependent
interactions with the FHA domain of the NBN component of the MRN complex (28-32).
Reproduced with permission from AACR.
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1.4

CK2 and DNA Damage Response & Repair Pathways
Another manner in which CK2 may contribute to the regulation of cancer cell

survival that might be exploited for intervention is through its involvement in DNA damage
response (DDR) and DNA repair pathways (Figure 1.2 B). In this respect, recent large-scale
phosphoproteomic analyses of G361 melanoma cells and GM00130 B lymphocyte cells
treated with the radiomimetric drug neocarzinostatin or with ionizing radiation to induce
DNA double-stranded breaks (DSBs) respectively, demonstrated a dynamic response in
motifs preferential for CK2 phosphorylation in many proteins. These results reveal a
previously under-appreciated role for CK2 as an important mediator in the cellular response
to DSBs (35, 36). Other indications that CK2 is involved in DDR and DNA repair pathways
include the demonstration that CK2α localizes to perinuclear structures whereas CK2α’
becomes nuclear in response to DSBs caused by ionizing radiation (37). Some of the putative
CK2 substrates that are involved in DDR are scaffold proteins such as mediator of DNA
damage checkpoint 1 (MDC1), where phosphorylation of serine-aspartate-threonine repeats
regulates retention of the MRE11A-RAD50-NBN (MRN) complex at DSBs through
interactions with Forkhead-associated (FHA) domains in the NBN (Nijmegen breakage
syndrome protein 1) component of the MRN complex (28, 29). Another critical interaction
for NBN is co-localization to the nucleolus which is dependent on the phosphorylation of
TCOF1 by CK2 at threonine 210, independent of MRE11A (30, 31). In terms of regulating
processes tasked with repairing damaged DNA, the phosphorylation of XRCC1 by CK2 is
required for single-strand break repair (38) and phosphorylation of XRCC4 is necessary for
non-homologous end joining repair (39). In homologous recombination, phosphorylation of
RAD51 by PLK1 at serine 14 primes the phosphorylation of threonine 13 by CK2, regulating
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binding to the NBN component of the MRN complex and facilitating recruitment of RAD51
to damaged DNA (32). In another recent study, it was determined that the phosphorylation of
a deubiquitylase OTUB1 by CK2 is necessary for its nuclear accumulation in order to
promote the formation of TP53BP1 repair foci at DSBs (40). While there are undoubtedly
many details regarding its roles in DDR and DNA repair pathways that remain to be
elucidated, these examples demonstrate that CK2 may have an important role in several
discrete aspects of these processes. A recurring theme that is highlighted by these examples
is that phosphorylation by CK2 promotes phosphorylation-dependent interactions such as
those involving the FHA domain of the NBN component of the MRN complex. Overall, the
widespread involvement in these processes could be relevant to the development of strategies
that neutralize the advantages or exploit the unique vulnerabilities of cancer cells.
1.5

Protein Kinase CK2 Inhibitors
As CK2 is implicated in a number of fundamental biological processes, and found at

varying levels of deregulation in human cancers, there has been widespread interest in
targeting this kinase therapeutically (10, 14). While there are many inhibitors described in the
literature (41, 42), the following sections focus on the use of CX-4945.
1.5.1 CX-4945: an ATP-competitive CK2 Inhibitor in Clinical Trial
CX-4945 was developed by Cylene Pharmaceuticals Inc. and is a potent and selective
ATP-competitive inhibitor (Ki = 0.38 nM for CK2α and CK2α’ with an IC50 of 1 nM) with no
extensive inhibitory activity detected against a panel of 238 kinases (43, 44).
Characterization of its in vitro effects revealed varying degrees of activation of caspase 3 and
caspase 7 in cancer cells with no detectable change of caspase 3/7 activity in normal cells
(44). Interestingly, CX-4945 elicited differential effects on the cell cycle with BT-474 breast
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cancer cells arresting in G2/M transition and BxPC-3 prostate cancer cells arresting in G1
(44). In vitro studies employing CX-4945 in combination with gemcitabine or cisplatin
revealed enhanced anti-proliferative effects in A2780 and SKOV-3 ovarian cancer cells.
Anti-proliferative activity was 23-38% higher based on a Bliss Independence model when
CX-4945 was added to cells after treatment with gemcitabine or cisplatin. These treatments
were also accompanied by decreased phosphorylation of the CK2 substrates XRCC1 and
MDC1 and accumulation of single-stranded and double-stranded DNA breaks (45). These
data are in agreement with the observations of CK2 localizing to the nucleus in response to
double-stranded breaks and for the role of CK2 in the DDR and DNA repair mechanisms (37,
38, 46, 47). Currently CX-4945 is in Phase I/II clinical trial in the U.S., South Korea and
Taiwan for the treatment of cholangiocarcinoma (bile duct cancer) in combination with
gemcitabine and cisplatin (ClinicalTrials.gov Identifier NCT02128282). The aim of this trial
is to determine its maximum tolerable dose in patients followed by a randomized Phase II
assessment using CX-4945 in combination with gemcitabine and cisplatin versus the
standard of care.
1.5.2 Emerging Prospects for Combinatorial Treatments Involving CK2 Inhibition
CX-4945 has been used in combination with other agents and has shown promise for
targeting a number of malignancies. For example, CX-4945 has been studied in vitro in
combination with DNA-damaging agents such as in acute myeloid leukemia cell lines and
patient-derived leukemia cells (48). In another study of hematological malignancies, CX4945 demonstrated a significant decrease in cell viability of patient-derived chronic
lymphocytic leukemia (CLL) cell lines in vitro (49). When CX-4945 was combined with GS1101 (PI3KD inhibitor), ibrutinib (BTK inhibitor), or fludarabine, synergistic responses were
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observed in CLL cell lines that were not observed in the unpaired treatments with
combination indices (using the Chou-Talalay method) of 0.46, 0.56 and 0.30 for CX-4945
and GS-1101, ibrutinib and fludarabine, respectively. Combinations of CX-4945 and
bortezomib using patient-derived cells from multiple myeloma and mantle cell lymphoma
also demonstrated enhanced mitochondria dependent apoptosis associated with suppression
of NFKB1 and STAT3 target genes leading to 50% reduction of NOS2 and BCL2 gene
expression (50). In other in vitro cell models of cancer such as A431 epidermal carcinoma
cells and H2170 lung cancer cells, combining erlotinib and CX-4945 resulted in suppression
of Akt1 phosphorylation in addition to down-regulation of phosphorylation sites on Akt1 and
mTOR substrates (51). Combined treatment resulted in 3-fold increases in apoptosis as
determined by caspase-3 and caspase-7 activity assays in comparison to treatment by CX4945 or erlotinib alone. This enhanced anti-proliferative effect was also demonstrated in
mouse xenograft models with the greatest reduction in tumor volume resulting from
combined treatment in both A431 and H2170 xenograft mice (51).
Since resistance is commonly observed with both chemotherapy and targeted therapy
involving kinase inhibitors, inhibition of CK2 has also been explored as a strategy for
overcoming both de novo resistance and acquired resistance. Analysis of several multidrugresistant cell lines revealed that CX-4945 sensitized cells to vinblastine and doxorubicin,
resulting in reduction of cell viability by 50% when treating with vinblastine and a two-fold
increase in doxorubicin accumulation in resistant cells (52). These results indicate that CK2
inhibition may have utility for over-coming de novo resistance.
There is also mounting evidence to suggest that CK2 inhibition may be effective to
combat adaptive resistance. Investigation of imatinib-resistant chronic myeloid leukemia cell
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lines revealed two-fold higher protein and activity levels of CK2, along with increased
localization of CK2α and CK2β to the cytoplasm of imatinib-resistance cells in comparison
to imatinib-sensitive cells (53). Interestingly, treatment with CX-4945 abrogated CK2α and
Bcr-Abl interaction as determined by co-immunoprecipitation and glycerol gradient
sedimentation leading to the induction of apoptosis in resistant cell lines at concentrations
that failed to promote PARP cleavage in imatinib-sensitive CML. Furthermore, treatment of
imatinib-resistant CML cells with CX-4945 or siRNA targeting CK2α promoted higher
sensitivity to lower concentrations of imatinib, suggesting that the kinome had adapted in
response to Bcr-Abl inhibition by imatinib leading to increased dependence on CK2 activity
(53). In an in vitro cell model of T-cell acute lymphoblastic leukemia, CX-4945
downregulated the unfolded protein response as determined by HSPA5 expression and
caused increased ERN1, phosphorylated EIF2S1, and DDIT3 indicating ER stress. When
paired with thapsigargin or temsirolimus the synergistic cytotoxicity was further potentiated
in these cell based assays (54). More recently, analysis of acquired resistance in triple
negative breast cancer using SUM149 and SUM159 cell lines revealed that resistance to the
BET bromodomain inhibitor JQ1 was associated with increased binding of BRD4 to MED1
in a bromodomain-independent manner, and dependent on BRD4 phosphorylation by CK2α,
which keeps transcriptional regulation of genes promoting cellular proliferation active (55).
Utilization of CK2 inhibitor or protein phosphatase PP2A activators such as perphenazine
decreased phosphorylation of BRD4, suggesting a rationale combination for tackling BET
bromodomain inhibitor resistance in triple negative breast cancer. Collectively, these
observations raise the prospect that CK2 inhibitors could be utilized to enhance the
effectiveness of other interventions.
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1.6

Mass Spectrometry-Based Proteomics

The study of the protein-encoded complement of the genome on a global scale is referred to
as proteomics. This analysis also includes the corresponding factors that can regulate protein
function, such as posttranslational modifications and abundance. Mass spectrometry-based
proteomics takes advantage of the ability to acquire high quality spectra of analyte derived
from protein sources in complex samples such as human cells or tissue (56). This analysis
can be accomplished rapidly with current mass spectrometry instrumentation enabling the
identification of thousands of proteins in a limited amount of time (57). The most common
form of mass spectrometry-based proteomics is the “bottom up” approach, where proteins are
digested by proteases resulting in short peptides that are then analyzed (Figure 1.3). Peptides
are delivered to the mass spectrometer using micro or nano-scale high-performance liquid
chromatography columns. Peptides injected onto the column are eluted using an increasing
gradient of organic solvent which separates the peptides on the basis of hydrophobicity when
using stationary matrices such as reversed-phase C18 material. The eluted peptides are then
ionized at the point of entry to the mass spectrometer by the application of electric potential
across an emitter needle, using a process called electrospray ionization (58). The ionized
peptides are measured on the basis of their mass-to-charge (m/z) ratio. In data-dependent
analysis, peptide ions are detected and analyzed typically in two stages. In the first stage
(MS1), the mass analyzer performs a survey scan selecting specific precursor ions, usually on
the basis of abundance. These selected precursor ions are then fragmented in a collision cell
and detected in a second mass analyzer (MS2). A commonly used fragmentation mode,
collision-induced dissociation (CID), creates ion fragments through collisions with inert gas
molecules, generating ions that originate from the amino terminus (b ions) and carboxy
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terminus (y ions). The basis of peptide sequence identification results from the calculation of
the differences in mass observed between fragment ions, which can represent an amino acid
(59). The assigned precursor and fragment masses can then be searched against a database to
identify the sequence and can be statistically validated using decoy search strategies to
estimate the rate of false positive identification (reviewed in (60, 61)). A complete review of
the mass spectrometry instrumentation and technology used to generate data presented in this
thesis is beyond the scope of this thesis and can be found in (62-64).
1.7

Quantitative Proteomics

Quantitative proteomic strategies can be employed to better understand the context of the
biological system being analyzed. This approach moves away from simply identifying a
protein of interest using mass spectrometry towards an approach that enables characterization
of dynamic features of the protein or system of interest. Quantitative strategies can be applied
at the protein or peptide level. Labeling techniques such as isobaric tags for relative and
absolute quantitation (iTRAQ) (65), tandem mass tags (TMTs) (66), or dimethyl labeling
(67) are performed at the peptide level. This results in peptides that can be distinguished in a
mass spectrometer between different conditions or treatments. A commonly used approach
involves labeling at the protein level in vivo in the system of interest. Stable isotopic labeling
of amino acids in cell culture (SILAC) involves the metabolic labeling of amino acids
containing 13C or 15N into the proteome of a cell (68, 69). By using arginine and lysine amino
acids that are labeled with “heavy”

13

C or

15

N isotopes and a protease such as trypsin that

cleaves after the c-terminus of arginine and lysine residues, one can obtain a sample where
theoretically all peptides are labeled (Figure 1.4). SILAC-labeled samples are mixed at a 1:1
ratio at the protein level prior to sample digestion and handling. This ensures that samples
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that were differentially treated within the biological context of interest undergo the same
handling steps and minimizes the likelihood of sample loss in one label versus the other.
Peptides from SILAC samples elute at the same time during chromatographic analysis, and
are distinguishable due to the difference in mass introduced by the presence of “heavy”
amino acid. The abundance of a peptide can then be determined by relative quantitation.
MaxQuant, a freely available mass spectra data analysis software can detect the threedimensional characteristics of a SILAC pair in MS1 using m/z, signal intensity and elution
time, enabling the accurate identification and quantitation of thousands of peptides detected
in an LC-MS/MS acquisition (70, 71).
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Figure 1.3 Identification of Peptides Using Mass Spectrometry
Peptides generated from protein samples using proteases such as trypsin can be ionized using
electrospray ionization and delivered into the mass spectrometer by liquid chromatography.
Ions are selected on the basis of abundance in MS1 during data-dependent analysis, and
fragmented for detection in MS2. CID fragmentation results in b and y ions. The difference
in mass from the resulting fragments can be used to identify the amino acid sequence of the
peptide.
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Figure 1.4 Quantitative Proteomics Using SILAC
SILAC enables the labeling of proteins in cellular systems using amino acids containing 13C
and 15N isotopes. When arginine and lysine amino acids are used as the source of metabolic
labeling, proteolytic cleavage using trypsin will result in a sample of peptides that are labeled
with a “heavy” amino acid at the carboxy-terminus. SILAC labeled peptide pairs will elute at
the same time during liquid chromatography separation, and will be distinguishable in the
mass spectrometer due to the labeled amino acid-specific mass shift. Relative quantitation is
achieved during MS1 where a ratio can be calculated based on the intensity of each peptide
ion peak. Detection of peptide ion fragments in MS2 ensures appropriate sequence
identification.
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1.8

Phosphoproteomics
Phosphorylation is a posttranslational modification which can be dynamically

regulated through kinases and phosphatases. Quantitative phosphoproteomic strategies have
been successfully employed to study signaling networks involved in cell cycle regulation
(72) and the response to kinase inhibitors (73). Due to the nature of data-dependent
acquisition where peptide ions are selected based on abundance, unphosphorylated peptides
typically predominate the peptides selected for fragmentation and MS2 detection, therefore
limiting the analysis of phosphopeptides (74). Consequently, phosphopeptide enrichment
strategies are typically required to overcome this obstacle and enable detection of
phosphopeptides. One commonly used enrichment strategy is metal oxide affinity
chromatography using TiO2, which captures phosphopeptides through the interaction of the
phosphate anion in a “bridging-bidentate” mode with TiO2 (75). The selectivity of
enrichment is further enhanced by using acid modifiers such as lactic acid (76), during
washes and incubation steps which prevent the binding of non-phosphorylated peptides
through carboxylic groups. When coupled with a quantitative label such SILAC, the relative
comparison of the abundance of a phosphopeptide can enable the quantitation of
phosphorylated residues (referred to as phosphorylation sites) localized to that peptide.
Bioinformatics approaches can then be employed to assign kinase-substrate relationships
using linear motifs (77). A recent comprehensive review of phosphoproteomic strategies and
workflows is described in (78).
1.9

Chemical Proteomic Approaches to Study the Kinome

In addition to the development of phosphoproteomic profiling to monitor the phosphorylation
status of protein kinase substrates, complementary strategies have emerged to directly
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monitor the kinome. The capture of kinases using chemical biology approaches was first
demonstrated

using

adenosine-5’-(γ-4-aminophenyl)triphosphate-sepharose

affinity

chromatography to isolate MEK from rabbit skeletal muscle (79). This approach was further
advanced using ATP-competitive inhibitors to identify targets of cyclin dependent kinase and
glycogen synthase kinase-3, demonstrating the utility of this methodology to profile offtarget effects of kinase inhibitors (80, 81). Studies expanding on the types of inhibitor resins
available for chromatography have devised combinations of inhibitors that achieve broad
capture and selective capture of kinases. These latter developments have enabled the
identification of the broad impact of kinase inhibitors on the kinome and revealed target
profiles of clinical stage inhibitors (82). Quantitative applications using SILAC labeling have
also been used to monitor the changes in the phosphorylation status of the kinome during the
cell cycle, identifying regulated phosphorylation sites on kinases that were previously
uncharacterized in the regulation of the cell cycle (83). Building on this approach,
optimization of the kinase inhibitor mix utilized by Daub et al. (83) led to the development of
the Multiplexed Inhibitor Bead (MIB) protocol by Duncan et al. (84). MIBs have been used
as a means to capture and infer the activity of hundreds of active kinases (ie. the active
kinome) from cell extracts. With triple-negative breast cancer cells and mouse models, this
approach revealed activation of receptor tyrosine kinases such as PDGFRβ and DDR1 in
response to the MEK inhibitors selumetinib or trametinib, which in turn activated
downstream kinases capable of activating the MAPK pathway through an alternative route to
circumvent inhibition (84).
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1.10 Rationale for Study
With recent advances in mass spectrometry-based proteomics and the increased
sophistication of computational approaches, it is now possible to explore cellular responses
to kinase inhibition on a proteome-wide scale. In addition to identification of direct targets
of individual kinases within cells, phosphoproteomic studies are also revealing new
relationships between different kinases or kinases-mediated pathways within the complex
and intricate regulatory networks that orchestrate cellular processes. For example, in a
thyroid cancer cell line harboring the BRAF V600E mutation, phosphoproteomic analysis
following short-term treatment (15 or 30 minutes) with vemurafenib (PLX4032) or MEK
inhibitor selumetinib (AZD6244) revealed increased phosphorylation of numerous sites.
Interestingly approximately 50% of the up-regulated sites conformed to the CK2 consensus
motif suggesting that CK2 activity is impacted by inhibition of MAPK signaling (85).
Building on that observation, combination of CX-4945 with vemurafenib demonstrated a
synergistic effect in reducing cell viability by 60% in V600E mutant thyroid cancer cells and
in mutant melanoma cell lines. In another global phosphoproteomic study, CK2
phosphorylation sites had increased phosphorylation site stoichiometry in gefitinib-resistant
PC9 lung cancer cells in comparison to gefitinib-sensitive cells, in addition to having higher
phosphorylation stoichiometry than MAPK or EGFR regulated phosphorylation sites (86).
Collectively, these large-scale phosphoproteomics studies imply that CK2 may have an
important role in drug resistance mechanisms and offers new insights regarding pathways
that may be regulated or influenced by CK2.
In this respect, applications of proteomic and phosphoproteomic strategies for
profiling CK2 inhibitors would undoubtedly be invaluable in assessing the prospect of
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resistance to CK2 inhibition and revealing the relationships of CK2 with other constituents of
the regulatory kinase networks. Given the emergence of CX-4945 as a clinical-stage
inhibitor, it has become widely used in the CK2 field to study cellular processes that CK2 is
implicated in regulating. Therefore, an investigation into effect of CX-4945 on a global scale
is warranted, and characterization of the effects of CX-4945 in an unbiased manner will
highlight the CK2-dependent and independent effects in cells.
1.11 Thesis Objective
In chapter 2, development and optimization of a phosphoproteomics workflow was
performed. We identified that the use of specific types of sorbents for sample preparation can
impact the ability to enrich for phosphopeptides that match the CK2 consensus. We also
compared workflows to evaluate the utility of using chromatographic separation to
fractionate phosphopeptide mixtures prior to LC-MS/MS analysis and demonstrated that
fractionation did not dramatically improve the detection of phosphopeptides and that
omission of the chromatographic fractionation has the advantage of reduced sample handling
and instrument time. The sample preparation protocol was further refined by comparing two
different methods for proteolytic digestion of protein samples, with one method
outperforming the other in the number of phosphorylation sites identified.
In chapter 3, we performed unbiased phosphoproteomic profiling of the effect of CX4945 on HeLa cells using a quantitative SILAC strategy. This resulted in the identification of
several dynamic markers of CK2 activity that displayed larger magnitudes of dephosphorylation in comparison to a bona fide substrate, EIF2S2 Ser2 that has been
previously utilized as a biomarker for CK2 activity. CK2 phosphorylation sites were located
on several proteins involved in DNA repair and translation, highlighting the importance of
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CK2 in regulating these processes. Overall, interrogation of the phosphoproteome revealed a
broad impact on several kinases when kinase-substrate enrichment analysis was performed,
suggestive of both CK2-dependent and CK2-independent effects of CX-4945 in cells.
In chapter 4, we performed MIB profiling of the kinome in HeLa cells to corroborate
the phosphoproteomic data. This resulted in the identification of kinases downstream of
PI3K/Akt/mTOR pathway that are down regulated by CX-4945 treatment, and the
demonstration that the ERK MAPK pathway is activated following CX-4945 treatment.
Further studies were performed with an unrelated inhibitor of CK2, “Inhibitor VIII,” (Figure
1.5). These studies revealed that CX-4945 and Inhibitor VIII have some overlapping effects
but also putative divergent functions. In this respect, treatment with either CK2 inhibitor
resulted in activation of ERK whereas inhibition of the mTOR pathway was exclusively
observed with CX-4945. Additional characterization using flow cytometry and western
blotting revealed differential effects of these two inhibitors in cells, raising speculation about
the mechanism of action in cells.
Taken together, the proteomic characterization of cells treated with CX-4945 has
identified dynamic markers of CK2 activity and also revealed the broad impact of CX-4945
on the phosphoproteome which suggests that CK2 is intricately involved in regulatory kinase
networks and that CX-4945 may also elicit CK2-independent effects in cells.
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Figure 1.5 Structures of ATP-competitive CK2 Inhibitors CX-4945 and Inhibitor VIII
CX-4945 (5-((3-chlorophenyl)amino)benzo[c][2,6]naphthyridine-8-carboxylic acid) is
described in (43, 44). Inhibitor VIII (4-(2-(4-methoxybenzamido)thiazol-5-yl)benzoic acid) is
described in (87).
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2

Chapter 2 – Development of a Mass Spectrometry – Based Phosphoproteomics
Workflow

2.1

Introduction
The phosphorylation of proteins by protein kinases is a critical post-translational

modification required in the regulation of cellular homeostasis (88). Advances in mass
spectrometry have enabled not only the identification of phosphorylation sites but the
quantitative dynamics of this modification on a large scale (89). However, enrichment
strategies are still required in order to detect phosphorylated peptides and different options
exist such as immobilized metal ion affinity chromatography using iron (Fe3+) (90) or metal
oxide affinity chromatography using TiO2 (91).
Protein kinase CK2 is involved in a multitude of cellular processes by virtue of the number of
proteins that it can phosphorylate and is necessary for cell survival and proliferation (16).
The specificity determinants of protein kinase CK2 dictate the phosphorylation of target
protein substrates, with acidic residues such aspartic acid or glutamic acid in the n + 3
position (relative to the phospho-acceptor residue) serving as critical elements (92-95).
Bioinformatic analyses have demonstrated that in addition to the n +3 position, CK2
substrates generally display large stretches of acidic residues rendering sequences
hydrophilic in nature (15). Contemporary sample preparation methods in phosphoproteomic
workflows require steps for desalting of peptides prior to phosphopeptide enrichment (96,
97). The use of reverse-phased columns for desalting can affect the recovery of hydrophilic
peptides (98, 99). This poses a challenge for the detection of phosphorylated peptides that are
putative substrates of CK2. Therefore, the investigation of different solid phase extraction
(SPE) columns for peptide desalting was undertaken to determine if phosphorylated
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hydrophilic peptides containing a CK2 consensus sequence could be retained and later
detected by LC-MS/MS. A comparison of porous graphitic carbon (PGC) and octadecyl
carbon chain (C18) SPE columns was undertaken in combination with a strong cation
exchange chromatography (SCX) fractionation workflow (Figure 2.1). This resulted in the
generation of four datasets: phosphopeptides from samples fractionated using SCX and
without fractionation, respectively desalted by PGC and C18 SPE columns. Integrating a
combined PGC and C18 SPE desalting step, the phosphoproteomic workflow was further
developed by comparing the preparation of protein lysates using Filter Aided Sample
Preparation (FASP) or protein precipitation (PP) prior to phosphopeptide enrichment. This
enabled the evaluation of the respective protein preparation methods and their respective
effect in identifying phosphorylation sites and protein groups reproducibly.
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Figure 2.1 Schematic for Comparison of Phosphopeptide Enrichment Workflows.
Lysate from UTA6 cells was digested in-solution with trypsin and desalted with PGC or C18
SPE columns. 75% of peptides were fractionated by SCX chromatography prior to
phosphopeptide enrichment with TiO2 and 25% were directly enriched for phosphopeptides
using TiO2. All samples were analyzed by LC-MS/MS using a QExactive mass spectrometer
operated in data-dependent acquisition mode and resulting raw spectra were analyzed in
PEAKS 7.0.
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2.2

Results

2.2.1 Evaluation of PGC and C18 SPE for Phosphopeptide Identification
A comparative analysis of phosphopeptides derived from peptide mixtures that were
desalted by PGC or C18 SPE columns was performed to investigate the utility of
fractionation for a phosphoproteomics workflow. Analysis of unique variants of
phosphopeptides in PEAKS software (non-unique amino acid sequences, but unique patterns
of variable modifications) that were detected by LC-MS/MS revealed distinct but
overlapping sets of phosphopeptide identification between PGC and C18 SPE desalted
samples (Figure 2.2). PGC SCX-TiO2 yielded more phosphopeptides than C18 SCX-TiO2,
identifying a total of 3118 phosphopeptides of which 338 were shared by the C18 SCX-TiO2
method that in total only yielded 678 phosphopeptides. When comparing the respective SPE
sorbents with or without SCX fractionation, both the PGC and C18 methods without
fractionation outperformed the SCX-fractionation method in terms of phosphopeptide yield.
C18 TiO2 yielded 4,402 phosphopeptides identified, exceeding that of PGC TiO2 that
identified 3,842 phosphopeptides, with 1,560 phosphopeptides shared between the two
methods. Considering the increased yield of phosphopeptides from workflows without SCX
fractionation and the increased complexity of the SCX-fractionation workflows that require
multiple desalting steps in contrast to the single step desalt with the unfractionated samples,
we focused the comparison of phosphopeptides from unfractionated samples desalted with
PGC and C18.
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2.2.2 Comparison of Phosphorylation Motifs Obtained from PGC and C18 SPE
To compare the utility of PGC and C18 SPE columns for desalting tryptic digests
prior to phosphopeptide enrichment for the identification of hydrophilic phosphopeptides that
could be putative phosphorylation sites by CK2, we analyzed the phosphopeptides obtained
from the phosphoproteomic workflows using a bioinformatics tool, motif-x (100, 101).
Statistically significant over-represented motifs from modified serine residues were identified
in each of the samples (Figure 2.3). Both SPE columns retained phosphopeptides that were
enriched for phosphorylation motifs containing proline in the n +1 with comparable
performance based on the fold increase. However, the PGC SPE column exhibited the best
performance in the identification of acidic motifs reminiscent of the specificity determinants
of CK2 with two motifs matching the CK2 consensus sequence being enriched 61.87-fold
and 49.47-fold over the background frequency of serine residues in the human proteome.
This result demonstrates the utility of a different sorbent to achieve desalting prior to
phosphopeptide enrichment as opposed to a silica-based C18 reverse-phase material for the
purposes of identifying phosphopeptides that display the specificity determinants for
phosphorylation by CK2.
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Figure 2.2 Comparative Analysis of Phosphopeptides Identified Using Different Sample
Preparation Workflows
Phosphopeptides enriched from SCX-fractionated and unfractionated samples using TiO2
were analyzed by LC-MS/MS and searched in PEAKS 7.0. Phosphopeptide variants (unique
modification pattern) were considered for comparison between SCX-fractionated and
unfractionated samples that were desalted with PGC or C18 SPE columns.
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Figure 2.3 Analysis of Phosphoserine-containing Phosphopeptides with motif-x
Phosphorylated peptides from unfractionated samples desalted with PGC and C18 SPE
columns were analyzed using motif-x. Linear motifs were searched with a minimum number
of 20 occurrences and a 9 residue window (plus/minus 4 residues from the modified serine)
with a default value of significance threshold set to 0.000001 searching against the
International Protein Index human sequence database. The top 8 most abundant motifs are
listed in descending order based on foreground size (number of phosphopeptides matching
the motif) with respective fold increase values over the background frequency of serine
residues.
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2.2.3 Evaluation of FASP and PP Methods to Prepare Samples for Phosphopeptide
Enrichment
Building on the result that PGC exhibited increased performance in the identification
of hydrophilic phosphopeptides that conformed to the consensus sequence of CK2, the
investigation of the utility of two sample preparation methods that are widely used in the
proteomics field for the preparation of proteomic samples was undertaken (Figure 2.4). This
comparison was performed in order to determine if proteome sample preparation would
affect phosphoproteome yield. Filter Aided Sample Preparation (FASP) uses a filtration
concentrator (in this case with a molecular weight limit of 10,000 Da) to exchange buffers
during the process of reduction, alkylation and proteolytic digestion. Digested peptides are
then collected by spinning the concentrator in a centrifuge, resulting in removal of any
undigested peptides or proteins that are retained by the membrane (102-104). Protein
precipitation (PP) has been previously used in proteomics to remove non-compatible buffer
components or detergents from protein extracts prior to proteolytic digestion (105). This
strategy has also been adapted with the demonstration of the utility of on-pellet digestion
using a protease rather than re-suspension in a denaturing solution (106). Our
phosphopeptide enrichment protocol was also modified to include double incubations with
TiO2 based on literature reports of increased identification of phosphorylation sites using this
strategy (107). Furthermore, we followed the protocol from Kettenbach et al. (108), for
enrichment from unfractionated samples that employed the use of bulk TiO2 beads as a
substitute for the enrichment step in a spin-tip format.
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Figure 2.4 Schematic for Comparative Analysis of FASP and PP Workflows
(A) Protein lysate from HeLa Tet-Off cells was divided equally into two fractions and
processed using FASP or PP protocols. Proteome (2) and phosphoproteome (2) samples were
collected using both workflows and analyzed by LC-MS/MS using a Orbitrap Elite mass
spectrometer. (B) Overview of samples analysis. Each workflow was performed with
samples from 3 biological replicates that were each processed and analyzed in technical
duplicate. All acquired spectra were analyzed in MaxQuant v1.5.3.8.
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Taken together, the two methods identified a total of 6,153 phosphorylation sites with a
localization score greater than 0.75 (a maximum score is 1.00), with 63% overlap in terms of
the sites identified in at least one biological replicate from each of the workflows (Figure 2.5
A). A phosphorylation site is defined as an identified amino acid residue that is occupied by a
phosphate and can be identified from multiple phosphopeptides. Notably, twice as many
phosphorylation sites were exclusively identified using PP. The number of phosphorylation
sites identified in all three biological replicates using FASP and PP were 2,511 and 3,111
respectively (Figure 2.5 B). The percentage of biological replicates where the same site was
identified in independent LC-MS/MS acquisitions ranged from 41.4 – 48.9% for both
methods. (Figure 2.5 C). Slightly more than 50% of the identified phosphorylation sites were
present in all three biological replicates when using each method (Figure 2.5 D). In terms of
the identification of protein groups using FASP and PP, both methods achieved similar yields
in terms of the total number of protein groups identified in at least one biological replicate
(Figure 2.5 A). A protein group is defined as a collection of proteins that cannot be
individually distinguished based on the identified peptides, such as in the case of protein
isoforms. Both methods identified slightly over 5,000 protein groups in all three biological
replicates (Figure 2.5 B). The replicable identification of protein groups was much higher in
contrast to phosphorylation site identification, with approximately 90% of protein groups
being identified in both technical LC-MS/MS analyses (Figure 2.5 C), and approximately
92% of protein groups identified in all three biological replicates (Figure 2.5 D). In summary,
the use of protein precipitation in preparing samples for proteomic analysis is advantageous
given the increased number of phosphorylation sites yielded and the reduction in the number
of sample handling steps.
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Figure 2.5 Comparison of FASP and PP Workflows for Phosphoproteomics
FASP and PP workflows were compared on the basis of identification of phosphorylation
sites and protein groups. Phosphorylation sites were considered when P localization > 0.75.
(A) Comparison of sites and protein groups identified in at least one biological replicate. (B)
Number of sites and protein groups identified in at least one biological replicate and number
of sites and protein groups identified in all biological replicates. (C) Technical replicability of
identified sites and protein groups in the same biological replicate. (D) Percentage of
phosphorylation sites and protein groups that were identified in all three biological replicates.
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2.3

Discussion
The specificity determinants of CK2 substrates can render stretches of amino acid

sequences on a protein hydrophilic (15). In order to implement a phosphoproteomics
workflow capable of identifying phosphopeptides derived from CK2 substrates, we
compared solid phase extraction adsorbents for sample preparation and desalting in
combination with testing SCX-fractionation prior to phosphopeptide enrichment.
The use of SCX-fractionation appeared to be of limited utility considering the lower yield of
phosphopeptides identified when either C18 or PGC SPE columns were used for desalting
steps in comparison to samples that were not fractionated. Furthermore, considering the
amount of LC-MS/MS time required to analyze 11 SCX fractions (1100 minutes) in
comparison to 300 minutes for an unfractionated sample, the return on phosphopeptide
identification with limited sample handling and reduction of desalting steps renders the
unfractionated “shotgun” approach considerably more advantageous. The requirement for
desalting after SCX-fractionation may contribute to the lower yield of phosphopeptides. To
some degree, our results contrast a previous study. In this respect, the utility of SCXfractionation has been investigated previously in the application of phosphoproteomics (108)
where it was demonstrated that fractionation into 24 samples in comparison to an
unfractionated sample yielded a comparable number of unique phosphorylation sites. In an
SCX gradient, peptides with lower net charge elute earlier, with multiply-charged species
eluting later. Multiply-phosphorylated peptides will have a net charge less than zero and will
elute in the earliest fractions collected. Peptides generated with trypsin will have a net charge
of +2 at pH 2.7 (in the case of no missed cleavages) when accounting for the N-terminus and
C terminal arginine or lysine sidechain group, so a singly phosphorylated peptide will have a
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net charge of +1 (109). SCX fractionation may enable the separation of phosphopeptides
from non-phosphopeptides but this approach does not drastically outperform the
unfractionated approach in terms of phosphopeptides identified.
The utility of PGC SPE columns in desalting digested peptides was demonstrated in
the analysis of phosphorylation motifs identified using motif-x from unfractionated samples.
Although more phosphopeptides were identified using the C18 SPE columns, the
identification of phosphorylation motifs reminiscent of the specificity determinants of protein
kinase CK2 from porous graphitic carbon SPE columns was more prevalent when analyzing
the enrichment of phosphorylation motifs against a background of the human proteome. The
ability to enrich phosphopeptides matching the specificity determinants of protein kinase
CK2 using PGC is advantageous. Previous reports using graphite and porous graphitic
carbon as desalting adsorbents prior to LC-MS/MS analysis have also highlighted the utility
of this sorbent in phosphoproteomics (98, 99, 110).
The comparison of FASP and PP as methods to prepare proteomic and
phosphoproteomic samples for LC-MS/MS analysis highlighted similar yields in protein
group identification across all biological replicates that were processed. Furthermore, there
was similar technical replicability in terms of protein group identification from LC-MS/MS
run to run. Given that several unique peptides can identify a protein, the identification of
protein groups using a data-dependent acquisition method does not suffer the same
constraints that phosphorylation site identification does. Few phosphopeptides can contribute
to the identification of a phosphorylation site. This is reflective of the stochastic nature of
data-dependent acquisition and the identification of a labile post-translational modification
within the constraint of a minimum localization score of 0.75. This issue in data-dependent
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phosphoproteomics has been identified previously and one alternative to improve future
analyses within the context of this project would be targeted acquisition of precursor ion
although this precedes the discovery proteomics stage. Applications of targeted
phosphoproteomics have increased the identification of phosphosites in technical replicates
up to 88% (111). Compared to FASP, the protein precipitation (PP) approach yielded
approximately 24% more phosphosite identifications with the same amount of input material,
suggesting a better recovery of phosphorylated proteins when precipitating in comparison to
retention using centrifuge spin concentrators. FASP has been investigated by other groups in
addition to the development of newer protocols with adjustments made to the types of buffers
and detergents used for sample processing (112, 113) to increase sample recovery. In
addition to protocol evolution, the integration of multiple enzyme digestion to generate a
different pool of peptides has been incorporated (114) and warrants future investigation to
identify optimal combinations of proteases which would serve in the identification of
putative CK2 motifs on phosphopeptides.
The comparative analysis of sample preparation approaches prior to phosphopeptide
enrichment revealed the advantage of using unfractionated protein samples in addition to the
use of different adsorbent materials for peptide desalting. Considering the amount of
instrument time that is logged using a fractionated strategy, the unfractionated approach is
advantageous in the delivery of LC-MS/MS results in a timely manner. An unfractionated
approach for phosphoproteome enrichment within this time constraint also enables the
analysis of more time-points or cellular contexts. Future phosphoproteomic investigations
will incorporate C18 and porous graphitic carbon in combination with protein precipitation in
order to identify phosphopeptides conforming to the CK2 consensus sequence by LC-
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MS/MS. In summary, these analyses establish a foundation upon which the development of a
phosphoproteomic-workflow evolved in order to address the identification of putative CK2
substrates in future experiments.
2.4

Experimental Methods

2.4.1 Cell Culture
UTA6 cell line – U2-OS-derived UTA6 cells (a gift from Dr. Christoph Englert,
Forschungszentrum Karlsruhe, Germany, as previously described in (115)) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS),
penicillin (100 U/mL) and streptomycin (100 µg/mL) on 15 cm dishes. Cells were lifted off
the dish with PBS-EDTA (), centrifuged at 200 x g, rinsed with phosphate-buffered saline
(PBS), transferred to 1.5 ml micro-centrifuge tubes and snap frozen in liquid nitrogen before
storage at -80 °C until further use.
HeLa Tet-Off cell line – HeLa Tet-Off cells (Clontech) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10 % FBS, penicillin (100 U/mL) and
streptomycin (100 µg/mL) on 15 cm dishes.
2.4.2 Cell Lysis
UTA6 cell line – Cell pellets were lysed on ice for 30 minutes with denaturing lysis
buffer [1% octyl-β-D-glucopyranoside (Sigma-Aldrich), 100 mM ammonium bicarbonate
(Fluka) pH 8.5, 6 M urea (Sigma-Aldrich), 10% acetonitrile (ACN) (Fisher Scientific), 1 mM
β-glycerophosphate (Sigma-Aldrich), 1 µM okadaic acid (Bioshop), 25 mM sodium fluoride
(Sigma-Alrich), 1 µM microcystin-LR (Cayman Chemical), pepstatin (10 µg/mL) (SigmaAldrich)]. Lysates were spun for 10 minutes at 16,000 x g at 4 °C, upon which the
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supernatant was retained and protein concentration was determined using a Bradford assay
(Bio-Rad).
HeLa Tet-Off cell line – Media was aspirated from culture dishes and cells were
rinsed with ice cold PBS. Cells were lysed on ice in [1% octyl-β-D-glucopyranoside (SigmaAldrich), 50 mM Tris (tris(hydroxymethyl)aminomethane) (Bioshop) pH 8.5, 6 M urea
(Sigma-Aldrich), 25 mM β-glycerophosphate (check), 1 µM okadaic acid (Bioshop), 50 mM
sodium fluoride (Sigma-Aldrich), 1 µM microcystin-LR (Cayman Chemical), 10 mM sodium
orthovanadate (Aldrich), 5 mM sodium pyrophosphate (Sigma-Aldrich), pepstatin (10
µg/mL) (Sigma-Aldrich)]. Samples were sonicated 2 x 15 seconds on ice then spun for 10
minutes at 16,000 x g at 4 °C, upon which the supernatant was retained and protein
concentration was determined using a Bradford assay (Bio-Rad).
2.4.3 Sample Preparation for Comparison of Unfractionated vs. Strong Cation
Exchange-Fractionated Phosphoproteome of UTA6 Cells
Protein lysate from UTA6 cells (a total of 20 mg) was divided into microfuge tubes in 2.5 mg
aliquots and processed for in-solution digestion. Samples were reduced with 10 mM DTT
(Sigma Aldrich) for 45 minutes at room temperature and then alkylated with 40 mM
iodoacetamide (IAA) (Sigma Aldrich) in the dark for 45 minutes at room temperature,
followed by quenching the reaction with the addition of 10 mM DTT for 45 minutes at room
temperature. Samples were then diluted 1:4 using 50 mM ammonium bicarbonate pH 8.5
(ABC) and digested overnight for 18 hours at 37 °C with trypsin (Pierce) at a ratio of 1:100
(w/w). The next morning the reaction was stopped by the addition of 10% formic acid (FA).
Peptides were desalted by solid phase extraction (SPE) using porous graphitic carbon (PGC)
(HyperSep Hypercarb, Thermo Scientific) and C18 (Strata, Phenomenex) columns. PGC
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columns were activated with 3 x 1 mL of 70% (v/v) ACN, 0.1% (v/v) FA, followed by 3 x 1
mL with 0.1% (v/v) FA. 10 mg of digested peptides were loaded on each column followed by
washing with 3 x 1 mL of 0.1% (v/v) FA and eluted using 1 mL 70% (v/v) ACN, 0.1% (v/v)
FA. C18 columns were activated with 3 x 1 mL of 0.1% FA (v/v) in ACN, followed by 3 x 1
mL of 0.1% (v/v) FA. 10 mg of digested peptides were loaded on columns followed by 3 x 1
mL of 0.1% (v/v) FA and eluted using 1 mL 50% (v/v) ACN, 0.1% (v/v) FA. Samples were
then concentrated in a vacuum centrifuge until near-dryness and reconstituted in 0.1% (v/v)
FA. 75% of the sample was designated for fractionation by strong cation exchange (SCX)
chromatography with 25% of the sample designated for immediate phosphopeptide
enrichment.
2.4.4 Offline Fractionation of Digested UTA6 Peptides Using Strong Cation Exchange
Chromatography
Peptides desalted by C18 and PGC SPE columns were reconstituted in 100 µL of 0.1
FA and fractionated offline in SCX mode using a poly(2-sulfoethyl aspartamide) column
(100 x 4.6 mm, 5 µm, 200 Å) (PolySULFOETHYL A, PolyLC Inc.) connected to an Agilent
1100 HPLC with quaternary pump at a flowrate of 1.5 mL/min, monitoring absorbance at
220 nm. Mobile phase A consisted of 10 mM KH2PO4 pH 2.7, 20% ACN (v/v) and mobile
phase B consisted of 10 mM KH2PO4 pH 2.7, 500 mM KCl, 20% ACN (v/v). Fractionation
was performed using an 85 minute method consisting of a linear gradient as follows: 0% B
from 0 to 13 minutes, 25% B from 14 to 43 minutes, 100% B from 44 to 53 minutes, 100% B
from 53 to 60 minutes, with fractions collected every minute. Samples that were initially
desalted by PGC and C18 prior to SCX fractionation were again desalted by the respective
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SPE column after pooling both sets of respective samples into 11 fractions based on
absorbance at wavelength 220 nm.
2.4.5 Phosphopeptide Enrichment of UTA6 SCX-Fractionated and Unfractionated
Peptides
SCX-fractionated and unfractionated peptides prepared from UTA6 cell lysate were
enriched for phosphopeptides using a TiO2 phosphopeptide enrichment kit (Cat #88301,
Pierce) following the manufacturer’s instructions.
2.4.6 Filter Aided Sample Preparation (FASP) of HeLa Tet-Off lysates
Protein lysate (2 mg) from each biological replicate was reduced with 5 mM DTT for
30 minutes at room temperature. Centrifugal filter units with 10 kDa – cutoff membranes
(Amicon Ultra 15 mL, Millipore) were conditioned with 50 mM Tris pH 8.5, 8 M urea as per
the manufacturer’s instructions. Samples were then added to centrifugal filter units and
mixed with 4 mL of 50 mM Tris pH 8.5, 8 M urea and spun at 4, 925 x g for 15 minutes at
room temperature, repeating the addition of 4 mL 50 mM Tris pH 8.5, 8 M urea and
centrifugation. Samples were then alkylated with 10 mM IAA for 20 minutes in the dark,
followed by the addition of 4 mL 50 mM Tris pH 8.5, 8 M and centrifugation which was
repeated twice. The concentration of urea was then diluted by the addition of 4 mL 100 mM
Tris pH 8.5 and centrifugation, which was repeated twice. After the final dilution step trypsin
(Pierce) was added at a ratio of 1:100 (w/w) and samples were digested overnight for 18
hours at 37 °C. Samples were then added to new centrifugal filter units with 10 kDa – cutoff
(Amicon Ultra 0.5 mL, Millipore) which had been previously conditioned with 100 mM Tris,
pH 8.5 as per the manufacturer’s instructions. Samples were then spun at 14,000 x g until all
of the filtrate was collected, and acidified with 10% FA. An aliquot was desalted by C18
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StageTips (116), with the remainder of the digested peptides were desalted using C18 SPE
columns, from which the flow-through and wash fractions were retained and desalted on
PGC SPE columns. Samples were then concentrated in a vacuum centrifuge until neardryness and reconstituted in 0.1% (v/v) FA.
2.4.7 Protein Precipitation and On-Pellet Digestion (PP) of HeLa Tet-Off Lysates
Protein lysate (2 mg) from each biological replicate was precipitated by the addition
of 6 sample volumes of 10% trichloroacetic acid (TCA) (v/v) (BDH Chemicals) in acetone
(EMD Millipore) at – 20 °C overnight. Samples were spun at 16,000 x g for 10 min at 4 °C
to pellet precipitated protein, followed by removal of supernatant using vacuum aspiration,
and ice-cold acetone was added to wash the pellet, followed by centrifugation and a
subsequent wash step. Protein pellets were reconstituted in twice the original lysate sample
volume in 50 mM Tris-HCl pH 8.5, 0.02% ProteaseMAX (Promega) with 1:100 trypsin
(w/w) and digested for 4 hours at 37 °C with agitation in a shaking incubator. Samples were
then reduced with 5 mM DTT for 30 minutes, followed by alkylation with IAA for 20
minutes in the dark. Alkylation was quenched with 5 mM DTT for 30 minutes, and an
additional aliquot of 1:100 trypsin was added to samples before samples were incubated
overnight for 18 hours at 37 °C with agitation. The next day samples were acidified with
10% FA, spun at 3,000 x g to remove insoluble debris, after which a small aliquot was
desalted by C18 StageTips (116), while the remainder of the digested peptides were desalted
using C18 SPE columns, from which the flow-through and wash fractions were retained and
desalted on PGC SPE columns. Samples were then concentrated in a vacuum centrifuge until
near-dryness and reconstituted in 0.1% (v/v) FA.
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2.4.8 Phosphopeptide Enrichment of FASP and PP Digested Peptides
Reconstituted peptides desalted by C18 and PGC columns were measured using A280
absorbance on a Nanodrop (Thermo Scientific) to estimate peptide yield and combined.
Samples were adjusted to 2 M lactic acid (Sigma-Aldrich), 50% ACN (v/v) and mixed. Bulk
10 µM titanium dioxide (TiO2) beads (5020-75010, GL Sciences) previously washed and
incubated in 2 M lactic acid, 50% ACN (v/v) (binding buffer) were added to peptides at a
ratio of 4:1 (w/w) (400 µg of TiO2 beads per 100 µg of peptides) in micro-centrifuge tubes
and incubated for 30 minutes at room temperature with end-over-end rotation. Samples were
then spun at 8,000 x g for 1 minute, after which the supernatant was removed and transferred
to a new tube for a second incubation with TiO2 beads. After a second incubation with TiO2
beads for 30 minutes, the supernatant was retained, vacuum centrifuged, and desalted using
C18 micro-columns (C18 StageTips) (116). TiO2 beads were then washed twice by adding
500 µL of binding buffer and mixing vigorously using a vortex genie, followed by
centrifugation at 8,000 x g for 1 minute. TiO2 beads were then reconstituted in 500 µL of
50% ACN (v/v) and transferred to new micro-centrifuge tubes, followed by centrifugation at
8,000 x g for 1 minute, vacuum aspiration of supernatant and washed with 500 µL of 50%
ACN (v/v). This wash process was repeated for a total of three times. Phosphopeptides bound
to the TiO2 beads were eluted with two volumes of 300 µL of 5% NH4OH (v/v) (Fluka), 50%
ACN (v/v) (elution buffer) using centrifugation to pellet the beads in order to remove the
eluate. The eluate was passed through a StageTip containing one layer of C18 material by
centrifugation at 3000 x g for 2 minutes to retain any TiO2 beads, followed by the addition of
100 µL of 80% ACN (v/v). Filtered eluate was concentrated using vacuum centrifugation
until near dryness and reconstituted in 1% FA.
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2.4.9 LC-MS/MS Data Acquisition of UTA6 SCX-Fractionated and Unfractionated
Phosphopeptides
Samples were injected using a NanoAcquity UPLC (Waters) onto a Symmetry C18
trapping column (20 mm x 180 µm i.d., 5 µm, 100 Å) at a flow rate of 10 µL/min in 99%
mobile phase A (0.1% FA (v/v), 1% mobile phase B (0.1% FA (v/v) in ACN) for 4 minutes.
Samples were then separated on a NanoAcquity Peptide BEH C18 analytical column (250
mm x 75 µm i.d., 1.7 µm, 130 Å) at a flow rate of 300 nL/min by a linear gradient of
increasing mobile phase B. Fractionated samples were separated using a gradient from 7.5%
to 37.5% mobile phase B over 60 minutes (total run time 100 minutes per sample) and
unfractionated samples were separated using a gradient from 5% to 37.5% mobile phase B
over 240 minutes (total run time 300 minutes per sample). Separated peptides were ionized
using a nano-Electro Spray Ionization source connected to the analytical column by a fusedsilica capillary emitter (New Objective). Ionized peptides were analyzed using a QExactive
Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Scientific) operated by Thermo
XCalibur (software version 2.2.1.1646) in data-dependent mode. Full MS1 scans were
performed at 70,000 resolution, scanning from 400 – 1800 m/z with AGC set to 1 x 106 ions
and an isolation window of 4.0 m/z. The top 12 most abundant ions were selected for MS2
for SCX-fractionated samples and the top 24 most abundant ions were selected for MS2 for
unfractionated samples. A lock mass ion was enabled for 445.120025 m/z (117). Maximal
injections times for MS1 acquisition was 120 ms and 30 ms for SCX-fractionated and
unfractionated samples, respectively. Peptide ions were fragmented using HCD with NCE set
to 23% and data-dependent MS2 scans were performed at 17,000 resolution with a dynamic
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exclusion window of 60 seconds. Maximal injection times for MS2 acquisition was 120 ms
and 100 ms for SCX-fractionated and unfractionated samples, respectively.
2.4.10 LC-MS/MS Data Acquisition of HeLa Tet-Off FASP and PP Phosphopeptides
Samples were injected using a NanoAcquity UPLC (Waters) onto a Symmetry C18
trapping column (20 mm x 180 µm i.d., 5 µm, 100 Å) at a flow rate of 10 µL/min in 99%
mobile phase A (0.1% FA (v/v), 1% mobile phase B (0.1% FA (v/v) in ACN) for 4 minutes.
Samples were then separated on a NanoAcquity Peptide BEH C18 analytical column (250
mm x 75 µm i.d., 1.7 µm, 130 Å) at a flow rate of 300 nL/min by a linear gradient of
increasing mobile phase B from starting condition 7.5% to 25% for 180 minutes, followed by
25% to 32.5% for 40 minutes, and culminating at 60% at 240 minutes. Separated peptides
were ionized using a nano-Electro Spray Ionization source connected to the analytical
column by a fused-silica capillary emitter (New Objective). Ionized peptides were analyzed
using a Orbitrap Elite Hybrid Ion Trap-Orbitrap mass spectrometer (Thermo Scientific)
operated by Thermo XCalibur (software version 2.7.0.1094) in data-dependent mode. Full
MS1 scans were performed at 120,000 resolution, scanning from 400 – 1450 m/z with AGC
set to 5 x 102 ions and an isolation window of 1.0 m/z. The top 20 most abundant ions were
selected for MS2. A lock mass ion was enabled for 445.120025 m/z (117). Maximal injection
time for MS1 acquisition was 200 ms and 50 ms for MS2. Peptide ions were fragmented
using CID with NCE set to 35% with activation time set to 10 ms and a Q value of 0.25.
Data-dependent MS2 scans were acquired in the linear ion trap using rapid scan selection,
with a dynamic exclusion window of 60 seconds.
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2.4.11 Data Analysis of UTA6 SCX-Fractionated and Unfractionated Phosphopeptides
Raw mass spectra were analyzed in PEAKS version 7.0 (Bioinformatics Solutions
Inc.) (118, 119). Once loaded in PEAKS, mass spectra were refined and analyzed by de novo
sequencing with the following parameters; parent mass error tolerance 20.0 ppm, fragment
mass error tolerance 0.02 Da, enzyme specificity trypsin, fixed modification cysteine
carbamidomethylation (+ 57.0215), variable modifications methionine oxidation (+15.9949),
asparagine and glutamine deamidation (+0.9840 Da), serine and threonine phosphorylation
(+79.9663). The maximum number of variable modifications was set to 4. Following de novo
sequencing, data were searched against the UniProt sequence database (homo sapiens taxon,
accessed on March 11, 2014) using the same parameter constraints as de novo sequencing in
addition to 3 maximum missed cleavages for sequence matching. Peptide spectrum matches
were restricted to a 1% false discovery rate (FDR) threshold against a target-based decoy
database. Identified phosphopeptides were compared amongst the four datasets (SCXfractionated and unfractionated samples desalted by PGC or C18) for shared or
complementary sets of phosphopeptides. Using motif-x (100, 101), identified peptide
sequences from PGC and C18 unfractionated samples that were exported from PEAKS were
searched for statistically over-represented linear motifs centered on phosphorylated serine
residues against the human proteome fasta sequence database of the International Protein
Index built into motif-x. Linear motifs were considered with a minimum number of 20
occurrences and a 9 residue window (plus/minus 4 residues from the modified serine) with a
default value of significance threshold set to 0.000001.
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2.4.12 Data Analysis of HeLa Tet-Off FASP and PP Phosphopeptides
Raw mass spectra files were analyzed in MaxQuant version 1.5.3.8 (70, 71, 120) and
searched against the Uniprot sequence database (homo sapiens taxon, accessed on June 10,
2015). Mass tolerances were set to 4.5 ppm for the parent ion mass (MS) and 0.5 Da for the
fragment ion mass (MS/MS). The minimum number of amino acids in a peptide was set to 7,
with a peptide spectrum match (PSM) and protein match set to 1% FDR and protease
selectivity for trypsin/P. A maximum number of 3 missed cleavages was selected. The option
for second peptide search was selected, as was the use of “Match Between Runs” for
respective pairs of samples between biological replicates, using the default matching
parameters. A maximum number of variable modifications per peptide was 5, with
methionine oxidation (+15.9949), asparagine and glutamine deamidation (+0.9840 Da), and
serine and threonine phosphorylation (+79.9663) selected. Cysteine carbamidomethylation (+
57.0215) was set as a fixed modification. Raw mass spectra files were defined as separate
groups using the experimental setup option. The minimum score for modified peptides was
set to 40, and the decoy-database setting was “Revert.” Output data from MaxQuant was then
loaded into Perseus version 1.5.2.6 (121). For the comparison of proteome data between
FASP and PP, the “proteinGroups.txt” file was first removed of entries marked as reverse
decoy database hits, contaminants, and protein identifications that were only matched to
modified peptides. Proteins were considered identified in each biological replicate if
identified in at least one of two technical replicates. For the comparison of the
phosphoproteome data between FASP and PP, the “Phospho (ST)Sites.txt” file was removed
of entries marked as reverse decoy database hits and filtered to only contain phosphorylation
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sites with localization probability greater than 0.75. Phosphosites were considered identified
in each biological replicate if identified in at least one of two technical replicates.
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Supplemental Figure 2.1 Companion to Figure 2.2
Chromatograms for SCX separation of peptides desalted using PGC (top) and C18 (bottom.)
Peptides were separated at a flow-rate of 1.5 mL/min, monitoring absorbance at 220 nm.
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3

Chapter 3 – Investigation of the Phosphoproteome in Response to CX-4945
Treatment

3.1

Introduction

It is estimated that potentially 700,000 phosphorylation sites may exist in the human
proteome (6). Furthermore, current “deep” proteomic profiling methods can identify up to
50,000 phosphorylation sites in human cells, representing three quarters of the proteins that
are detectable by mass spectrometry (7). The regulation of phosphorylation is a central
component in maintaining cellular homeostasis and is regulated by protein kinases which
catalyze the transfer of phosphate from ATP to serine, threonine or tyrosine residues (122).
Not surprisingly, these enzymes have quickly emerged as potential therapeutic targets of
interest for the treatment of a number of human diseases (9). Protein kinase CK2 has
attracted interest as a potential therapeutic target since it has been identified as a kinase that
is expressed at high levels in different types of human cancers (16). A recent report has also
noted that de-regulation of expression exists at the transcript level for the catalytic and
regulatory subunits of CK2 (14). The first orally-bioavailable inhibitor of CK2, CX-4945
(44), recently entered clinical trial for the treatment of cholangiocarcinoma in combination
with gemcitabine and cisplatin, and is touted as a highly selective and specific inhibitor of
CK2 (123). CX-4945 has been used extensively in the literature in different models of
multiple myeloma, lymphoma, and leukemia (50, 53, 54, 124, 125), and these studies have
implicated CK2 activity in the regulation of different pathways. Characterization of the
impact of CX-4945 on a cellular phosphoproteome would enable a better understanding of
the processes and pathways that that enable cell death via CK2 inhibition. Additionally, it
would allow for an unbiased assessment of the potential for the regulation of other kinases
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considering this inhibitor is ATP-competitive. To date, proteomics strategies have not been
applied for characterizing the phosphoproteome of cells treated with CX-4945, and the most
recent studies with an inhibitor of CK2, quinalizarin, have not capitalized on translational
capacity due to its limited clinical utility (126, 127).
In this chapter the phosphoproteomics workflow that was optimized previously in
Chapter 2 is used to perform unbiased quantitative phosphoproteomic profiling of HeLa cells
treated with CX-4945 within a window of 240 minutes. SILAC (Stable Isotopic Labeling of
Amino Acids in Cell Culture) was utilized in order to perform relative quantification of the
phosphoproteome and proteome. To identify phosphorylated substrates that could serve as
dynamic markers of CK2 activity, a bioinformatics approach was undertaken and a kinasesubstrate prediction tool, KinomeXplorer (77) was utilized. In order to gauge the impact of
CX-4945 treatment on the phosphoproteome and to identify kinases-substrate relationships
that were perturbed in response to CX-4945 treatment, the PHOXTRACK tool (128) was
also employed. A global assessment of the biological processes and pathways with
phosphorylation sites perturbed by CX-4945 was performed using gene enrichment analysis
with g:Profiler (129). Collectively, these analyses reveal a broad impact of CX-4945 on
several different processes and distinct areas of regulation.
3.2

Results

3.2.1 Evaluation of CK2 Inhibition Using a Bona-Fide Substrate EIF2S2
A previous study by Geiger et al. identified that amongst 11 commonly used cell line
models there is ubiquitous expression of proteomes (130). Taking into consideration the
availability of existing cell line models in our laboratory and the use of a commercially
available HeLa proteome standard for LC-MS/MS analysis, we performed experiments in the
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HeLa cell line. Prior to embarking on a quantitative phosphoproteomic analysis of CX-4945
in HeLa cells, we adapted the cell line in SILAC medium for a period of 7 days and 3 subpassages to ensure that proteins were isotopically-labeled to greater than 95% as is routinely
performed (69). We used medium containing proline to prevent arginine-to-proline
conversion (131). Heavy labeled samples were digested and raw spectra acquired by LCMS/MS, followed by analysis in MaxQuant to assess the extent of isotopic labeling of
proteins (70, 71, 120). The median incorporation efficiency was over 96% (Supplemental
Figure 3.13.1) and the distribution of incorporation amongst all peptides detected and
quantified was skewed towards 100% incorporation. Following confirmation of successful
incorporation of isotopically-labelled amino acids, a time-course experiment was performed
using CX-4945 at 20 µM up to 24 hours of treatment in HeLa cells to identify a window of
time in which inhibition of CK2 would precede secondary signaling events such as DNA
damage or apoptosis, given that CK2 has previously been demonstrated to regulate the
phosphorylation of constituents of the DNA damage and repair pathways (29, 37, 132, 133)
and implicated in the regulation of apoptotic pathways (27, 34). Confirmation of CK2
inhibition was based upon the phosphorylation status of a well-characterized bona fide
substrate, EIF2S2 (11, 134), for which a phospho-specific antibody was raised in our
laboratory. Western blotting with antibodies directed against phospho-EIF2S2 Ser2, PARP,
and γH2AX Ser139 identified a period of time up to 4 hours in which the lysates derived
from CX-4945 treated samples were comparable to an untreated sample in terms of
appearance of cleaved PARP and γH2AX Ser139 (Supplemental Figure 3.23.2), suggesting
that within this window of time the inhibition of CK2 preceded the activation of other
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signaling pathways which could interfere with the interpretation of events succeeding CK2
inhibition.
3.2.2 Unbiased Phosphoproteomic Evaluation of HeLa Cells Treated with CX-4945
Following confirmation of CK2 inhibition using anti-phospho-EIF2S Ser2 antibody to probe
unlabeled lysates derived from HeLa cells treated with CX-4945, SILAC labeled HeLa cells
were treated with 20 µM CX-4945 or with DMSO for periods of 60, 135, 180 and 240
minutes. These samples were separated by SDS-PAGE, transferred to membrane and probed
using antibodies against phospho-EIF2S2 Ser2, PARP, phospho-ATM Ser1981, and γH2AX
Ser139 (Supplemental Figure 3.33.3-3.5). Western blotting confirmed that over the timecourse of 240 minutes, the inhibition of CK2 using CX-4945 was apparent with the decrease
in phospho-EIF2S2 Ser2 signal. During the period in which CX-4945 treatment occurred,
CK2 inhibition was not secondary to events such as the activation of apoptosis or the
activation of DNA-damage. These processes would be apparent with the cleavage of PARP
or increase of γH2AX Ser139 respectively. By comparison, lysates derived from cells treated
with a promiscuous kinase inhibitor such as staurosporine or a chemical which induces DNA
damage such as neocarzinostatin, displayed activation of apoptosis and evidence of DNA
damage. Next, equal amounts of light and heavy lysates were combined and digested with
trypsin and Lys-C proteases, followed by desalting and phosphopeptide enrichment.
Proteome samples were retained as well. By combining samples prior to processing and
enrichment, bias in phosphopeptide abundance between a treated and a control sample was
eliminated. Quantitative analysis by mass spectrometry enables the MS1 peptide features to
be utilized to measure the difference in abundance between SILAC pairs of peptides, and the
MS2 spectrum confirms peptide sequence identity and phosphorylation site localization
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(Figure 3.1). In total, 48 fractions derived from four time-point datasets of three biological
replicates were analyzed by LC-MS/MS in technical duplicate (Figure 3.2 A). This resulted
in the identification and quantification of 3,003 phosphorylation sites and 2,805 protein
groups in three out of three biological replicates across all time-points that were profiled
(Figure 3.2 B, C, D). Phosphorylation sites were categorized on the magnitude of change and
whether the change was statistically significant based on a one-sample Student’s t test with
Benjamini Hochberg FDR of 0.05 for multiple hypothesis correction (Figure 3.2 C and
Supplemental Figure 3.63.6-3.9). Of these, sites which are predicted to be phosphorylated by
CK2 as identified using KinomeXplorer (77) constitute a small number of the sites that
decrease greater than log2 -1 (a two-fold change). To note, the magnitude of change in
phosphorylation of TOP2A at Ser1377, a well-characterized CK2 substrate (135), is
substantially greater when compared to EIF2S2 Ser2 at 60 minutes of CX-4945 treatment
and over the period of inhibitor treatment up to 240 minutes (Figure 3.3). Other
phosphorylation sites from bona fide CK2 substrates within this period of treatment do not
show as dynamic de-phosphorylation. This suggests preferential activity of phosphatases
directed towards sites of phosphorylation by CK2. The broader impact on the
phosphoproteome can be visualized using volcano plots (Figure 3.4-3.7), where it is evident
based on the distribution of phosphorylation sites that increase and decrease upon treatment
that CX-4945 elicits a dynamic phosphoproteome.

54
3.2.3 Dynamic Phosphorylation is Independent of Protein Abundance
In parallel with phosphopeptide analysis to investigate the phosphoproteome of HeLa
cells perturbed with CX-4945, proteomic samples were analyzed by LC-MS/MS as well to
quantify the proteome. When surveying the distribution of quantified proteins in each
particular time-point, the distribution of quantified protein group ratios falls within log2 -/+
0.5, suggesting that the proteome in general does not change in cells that are treated with CX4945 up to a period of 240 minutes (Supplemental Figure 3.10-3.13). Additionally, those
phosphorylation sites that were categorized as statistically significant were plotted against the
corresponding protein ratio (Figure 3.8-11) for each individual time-point dataset to confirm
that the change in the phosphoproteome is independent of protein abundance.
Phosphorylation sites identified as CK2 substrates showed dramatic decrease in
phosphorylation upon CX-4945 treatment and this was not due changes in protein
abundance.
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Figure 3.1 Phosphoproteomics Workflow to Investigate CX-4945 in HeLa Cells.
HeLa cells were adapted in SILAC media and treated with CX-4945 for a period up to 240
minutes. Lysates were mixed 1:1 and digested with trypsin and Lys-C, followed by
phosphopeptide enrichment and analysis by LC-MS/MS. Relative quantitation was
performed on raw mass spectra using MaxQuant and identified and quantified sites were
analyzed using bioinformatics tools to investigate kinase-substrate relationships.
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Figure 3.2 Experimental Layout and Data Summary
(A) Processing of treated and control samples for LC-MS/MS analysis resulted in four
fractions per biological replicate which were analyzed in technical duplicate. (B) Summary
of total number of spectra acquired. (C) Number of phosphorylation sites identified and
quantified in 3/3 biological replicates and number that changed in response to CX-4945 that
met significance criteria. (D) Number of protein groups identified in 3/3 biological replicates.
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Figure 3.3 Phosphorylation Dynamics of Identified CK2 Sites Using KinomeXplorer.
Subset of phosphorylation sites identified as CK2 substrates that were quantified in all
biological replicates and time-points. In each panel header a concatenated identifier
consisting of the protein Uniprot accession code, amino acid residue, sequence position of
the phosphorylation site and multiplicity is shown. Error bars denote standard deviation of all
three biological replicates quantified.
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Figure 3.4 Volcano Plot of Quantified Phosphorylation Sites from HeLa Cells Treated
with 20 µM CX-4945 for 60 Minutes.
Quantified phosphorylation sites were tested for significance using a one-sample Student’s ttest with FDR correction (<0.05). Points in grey exceed statistical significance cut-off. CK2
phosphorylation sites identified by KinomeXplorer are highlighted in orange. Labeled sites
exceed log2 -1 and are significant. Vertical dashed lines denote -1 and +1 Log2 cutoffs;
horizontal line denotes FDR threshold of P < 0.05.
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Figure 3.5 Volcano Plot of Quantified Phosphorylation Sites from HeLa Cells Treated
with 20 µM CX-4945 for 135 Minutes.
Quantified phosphorylation sites were tested for significance using a one-sample Student’s ttest with FDR correction (< 0.05). Points in grey exceed statistical significant cut-off. CK2
phosphorylation sites identified by KinomeXplorer are highlighted in orange. Labeled sites
exceed log2 -1 and are significant. Vertical dashed lines denote -1 and +1 Log2 cutoffs;
horizontal line denotes FDR threshold of P < 0.05.
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Figure 3.6 Volcano Plot of Quantified Phosphorylation Sites from HeLa Cells Treated
with 20 µM CX-4945 for 180 Minutes.
Quantified phosphorylation sites were tested for significance using a one-sample Student’s ttest with FDR correction (< 0.05). Points in grey exceed statistical significance cut-off. CK2
phosphorylation sites identified by KinomeXplorer are highlighted in orange. Labeled sites
exceed log2 -1 and are significant. Vertical dashed lines denote -1 and +1 Log2 cutoffs;
horizontal line denotes FDR threshold of P < 0.05.
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Figure 3.7 Volcano Plot of Quantified Phosphorylation Sites from HeLa Cells Treated
with 20 µM CX-4945 for 240 Minutes.
Quantified phosphorylation sites were tested for significance using a one-sample Student’s ttest with FDR correction (< 0.05). Points in grey exceed statistical significance cut-off. CK2
phosphorylation sites identified by KinomeXplorer are highlighted in orange. Labeled sites
exceed log2 -1 and are significant. Vertical dashed lines denote -1 and +1 Log2 cutoffs;
horizontal line denotes FDR threshold of P < 0.05.

62

Figure 3.8 Comparison of Phosphorylation Site vs. Protein Abundance in HeLa Cells
Treated with 20 µM CX-4945 for 60 Minutes.
Phosphorylation sites that were statistically significant were plotted against the respective
protein ratio. Displayed are the mean Log2 ratios for a phosphorylation site and the mean
Log2 ratio for the respective protein abundance, all derived from three biological replicates.
CK2 phosphorylation sites are highlighted in orange. Labeled sites exceed Log2 -1.
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Figure 3.9 Comparison of Phosphorylation Site vs. Protein Abundance in HeLa Cells
Treated with 20 µM CX-4945 for 135 Minutes.
Phosphorylation sites that were statistically significant were plotted against the respecrive
protein ratio. Displayed are the mean Log2 ratios for a phosphorylation site and the mean
Log2 ratio for the respective protein abundance, all derived from three biological replicates.
CK2 phosphorylation sites are highlighted in orange. Labeled sites exceed Log2 -1.
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Figure 3.10 Comparison of Phosphorylation Site vs. Protein Abundance in HeLa Cells
Treated with 20 µM CX-4945 for 180 Minutes.
Phosphorylation sites that were statistically significant were plotted against the respective
protein ratio. Displayed are the mean Log2 ratios for a phosphorylation site and the mean
Log2 ratio for the respective protein abundance, all derived from three biological replicates.
CK2 phosphorylation sites are highlighted in orange. Labeled sites exceed Log2 -1.
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Figure 3.11 Comparison of Phosphorylation Site vs. Protein Abundance in HeLa Cells
Treated with 20 µM CX-4945 for 240 Minutes.
Phosphorylation sites that were statistically significant were plotted against the respective
protein ratio. Displayed are the mean Log2 ratios for a phosphorylation site and the mean
Log2 ratio for the respective protein abundance, all derived from three biological replicates.
CK2 phosphorylation sites are highlighted in orange. Labeled sites exceed Log2 -1.

66
3.2.4 CX-4945 Treatment Affects Phosphorylation Mediated by Kinases Other Than
CK2
CK2 can regulate the activity of other kinases by phosphorylation of cdc37 Ser13
(136), which is a kinase-chaperone that can regulate client kinases concurrently with Hsp90
(137). CX-4945 itself is a small molecule ATP-competitive inhibitor, and could target other
kinases other than CK2 in the cell. Considering these points, kinase-substrate enrichment
analysis was performed using PHOXTRACK (128) to investigate the impact of CX-4945
treatment. This analysis was performed using information found in PhosphoSitePlus and the
kinase-substrate relationships that are listed (138). Phosphorylation sites quantified in each
time-point dataset were analyzed separately and Kolmogorov-Smirnov unweighted running
sum statistics were calculated. PHOXTRACK scores for a particular kinase reflect the
enrichment value as computed by running sum statistics for the set of phosphorylation sites
that are attributed to a particular kinases and are adjusted using the false-discovery rate
(FDR). Activation or inhibition of a particular kinase can be inferred by the trend of
attributed phosphorylation sites; whether these sites are trending as increased in
phosphorylation or decreased in phosphorylation. Analysis using PHOXTRACK revealed
kinases (FDR < 0.25) that were inhibited or activated as inferred by the quantification of
attributed phosphorylation sites in PhosphoSitePlus for the four time-point datasets (Figure
3.12). Interestingly, at 60 minutes of CX-4945 treatment, mTOR and Akt are down-regulated
with CDK1, CDK2 and LATS1 being up-regulated. The phosphorylation of several CK2
substrates suggests that there is inhibition of CK2 although the bioinformatics analysis
derived from information attributed in PhosphoSitePlus does not meet the FDR cut-off of
0.25. Notably, in agreement with previous analysis using KinomeXplorer, there are
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Figure 3.12 PHOXTRACK Analysis of Phosphorylation Sites Quantified at Each TimePoint.
Phosphorylation sites were analyzed using PHOXTRACK which uses Kolmogorov-Smirnov
unweighted running sum statistics to calculate activation or inhibition of a kinase based on
the assigned substrates in PhosphoSitePlus database . Shown are heat maps with kinases that
exceeded a FDR threshold of < 0.25 in each time-point.
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Figure 3.13 Quantified CK2 Phosphorylation Sites in PhosphoSitePlus from HeLa Cells
Treated with 20 µM CX-4945.
Phosphorylation sites listed as CK2 substrates in PhosphoSitePlus database are presented.
The mean log2 ratio from three biological replicates is used to calculate the change
represented by each bar for a given phosphorylation site.
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Figure 3.14 Quantified mTOR Phosphorylation Sites In PhosphoSitePlus from HeLa
Cells Treated with 20 µM CX-4945.
Phosphorylation sites listed as mTOR substrates in PhosphoSitePlus database are presented.
The mean log2 ratio from three biological replicates is used to calculate the change
represented by each bar for a given phosphorylation site.
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Figure 3.15 Quantified Akt Phosphorylation Sites in PhosphoSitePlus from HeLa Cells
Treated with 20 µM CX-4945.
Phosphorylation sites listed as CK2 substrates in PhosphoSitePlus database are presented.
The mean log2 ratio from three biological replicates is used to calculate the change
represented by each bar for a given phosphorylation site.
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substrates of CK2 that decrease in response to CX-4945 (Figure 3.13). Substrates of the
mTOR and Akt kinases also decreased in phosphorylation (Figure 3.14-3.15) including
EIF4EBP1 Thr46/Ser65/Thr70 and AKT1S1 Thr246, suggesting that CX-4945 downregulates the mTOR/Akt pathways, although at this point it is unclear whether this is the
result of a CK2-dependent or independent inhibition.
3.2.5 CX-4945 Impacts Distinct Biological Processes and Pathways in HeLa Cells
To investigate the biological processes and pathways that could be affected by CX-4945
treatment, gene enrichment analysis was performed using g:Profiler (129) and gene ontology
(GO) terms for biological processes (139), KEGG pathways (140), and Reactome pathways
(141) were queried. Statistically significant phosphorylation sites across the four time-point
datasets were pooled into three groups: those with quantified ratios less than log2 -1 (i.e. a
reduction in phosphorylation by more than 50%), greater than log2 +1 (increase in
phosphorylation by two-fold) and those sites that were identified as CK2 substrates which
decreased greater than log2 -1. Enriched terms were visualized using Cytoscape and the
EnrichmentMap plugin (Figure 3.16-3.17 – and Supplemental Figure 3.14-3.15)(142).
Processes that were identified from phosphorylation sites that decreased in response to CX4945 treatment are involved in mTOR signaling, ribosome biogenesis, RNA splicing,
cytoskeletal organization, chromosome condensation and nuclear envelope assembly (Figure
3.16 A). Processes that were identified from CK2 substrates were involved in DNA repair
and translation (Figure 3.16 B). Processes that were identified from phosphorylation sites that
increased in response to CX-4945 are involved in nuclear transport, RNA splicing, negative
cell cycle regulation,
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Figure 3.16 EnrichmentMap Network of Biological Processes Enriched from
Decreasing Quantified Phosphorylation Sites Using g:Profiler.
Phosphorylation sites that decreased across all time-points greater than log2 -1 were used for
gene enrichment using g:Profiler. Networks were constructed in Cytoscape with a similarity
score cut-off of 0.5 and a FDR q value of 0.005. Nodes represent GO pathways, processes
and functions and are connected by edges where edge thickness corresponds to the number of
genes shared between two different nodes. Labels and font size correspond with
overrepresented terms. (A) Phosphorylation sites that decreased in response to CX-4945. (B)
Phosphorylation sites identified as CK2 using KinomeXplorer.
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Figure 3.17 EnrichmentMap Network of Biological Processes Enriched from Increasing
Quantified Phosphorylation Sites Using g:Profiler.
Phosphorylation sites that increased across all time-points greater than log2 +1 were used for
gene enrichment using g:Profiler. Networks were constructed in Cytoscape with a similarity
score cut-off of 0.5 and a FDR q value of 0.005. Labels and font size correspond with
overrepresented terms.
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apoptotic execution and microtubule regulation (Figure 3.17). The topology of the biological
processes and pathways that are affected by CX-4945 suggests a broad network that could be
regulated by CK2, however complementary sets within phosphorylation sites that decrease
and those that are CK2 substrates suggests divergent function of CX-4945 with respect to
CK2-dependent processes.
3.3

Discussion
Protein kinase CK2 expression is de-regulated in different types of human cancers, as

evidenced by a recent study of mRNA expression data in the Oncomine database (14). CK2
is implicated in the regulation of different cellular pathways by virtue of the identification of
protein substrates bearing the specificity determinants for phosphorylation (15). Given the
signaling network that CK2 is involved in, it has emerged as a therapeutic target. CX-4945 is
the first clinical-stage, orally-bioavailable small molecule ATP-competitive inhibitor of CK2
(44). Therefore, we sought to use phosphoproteomics to profile CX-4945 treatment in HeLa
cells to identify dynamic markers of CK2 activity and to monitor the effect of CK2 inhibition
on signaling pathways, in addition to profiling potentially divergent (CK2 independent)
functions of CX-4945 in cells.
Initial profiling of CX-4945 in HeLa cells revealed a window of time of up to 240
minutes where signaling events associated with apoptosis or DNA damage were not
activated, suggesting CX-4945 dependent effects would be the primary stimulus for signaling
events occurring. Utilizing a phospho-specific antibody for the bona fide CK2 substrate
EIF2S2, confirmation of CK2 inhibition suggested that CX-4945 treatment antagonized CK2
activity in HeLa cells. Subsequent analysis of quantified phosphorylation sites that changed
in response to CX-4945 in HeLa revealed several sites that displayed dynamic levels of
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reduced phosphorylation to a greater extent than that of EIF2S2 Ser2. Among theses sites
that change dramatically, a well-characterized substrate of CK2 such as TOP2A Ser1377
(135), decreased approximately 8 times more than DMSO vehicle treatment, suggesting that
inhibition of CK2 was achieved. Utilizing KinomeXplorer and Phoxtrack, three
phosphorylation sites matching the specificity determinants of CK2 were quantified from
EIF2S2: Ser2, Ser67 and Thr111. Both Ser2 and Ser67 are annotated in the PhosphoSitePlus
database as substrates of CK2 and both have been previously validated in experimental
studies (134, 143). By comparison, although detected in previous studies, Thr111 as a
substrate of CK2 has remained unexplored. Thr111 shows the largest change in response to
CX-4945, and the rate of de-phosphorylation over the 240 minute treatment differs between
Ser2 and Thr111 (Ser67 was not quantified in all time-points), suggesting differential activity
towards these phosphorylation sites by protein phosphatases, given that CK2 has constitutive
activity in cells (16). Ser2 and Ser67 have been identified as substrates of protein
phosphatase-1 (144) while the phosphatase activity towards Thr111 remains to be
determined. Ser2 has been characterized as a CK2β-dependent phosphorylation site and
cannot be phosphorylated by the free catalytic subunit CK2α (11), which raises interesting
questions regarding the de-phosphorylation of sites that are dependent on holo-enzyme
activity versus catalytic subunits when cells are treated with an inhibitor of CK2. It should be
noted that a few CK2 phosphorylation sites appear to increase in response to CX-4945
treatment. This may be the result of a loss of phosphorylation on a multiply-phosphorylated
peptide which increases the stoichiometry of a corresponding doubly or singly
phosphorylated peptide at a different phospho-acceptor residue on the peptide. This trend has
been previously identified with a different inhibitor of CK2, quinalizarin (127). Another
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possibility might be the proximity of other phospho-acceptor residues serving as specificity
determinants for hierarchical phosphorylation by CK2 (145), that when de-phosphorylated
result in an apparent increase in phosphopeptide containing the CK2 phosphorylation site.
More importantly, the phosphorylation sites that demonstrate the largest change in dephosphorylation not only serve as useful indicators of activity in cells but also provide further
insight into the critical pathways that CK2 can regulate as these sites would be indicative of
rapid turnover in regards to phosphatase activity. Previous investigations into large-scale
phosphorylation stoichiometry in cells identified sites matching CK2 motifs possessing the
highest phosphorylation stoichiometry in comparison to other kinases identified (146). The
ability to quantify the proteome in parallel enabled the confident analysis of phosphorylation
sites displaying dynamic regulation as it was determined that protein abundance during the
length of CX-4945 treatment did not differ.
Treatment with CX-4945 results in a dynamic phosphoproteome, creating changes in
phosphorylation sites that can be attributed to kinases other than CK2. Interestingly, CK2 can
regulate the activity of other kinases through phosphorylation of cdc37 Ser13, which in
conjuction with Hsp90 can stabilize client kinases (136). Quantification of cdc37 Ser13
phosphorylation did not change dramatically in response to CX-4945 treatment at 60
minutes, suggesting that the dynamic regulation of phosphorylation sites attributed to other
kinases is not necessarily through a CK2-dependent inhibition mechanism via the
phosphorylation status of cdc37 Ser13. Analysis of the phosphoproteome using
PHOXTRACK revealed that the activity of kinases such as mTOR and Akt are downregulated upon treatment with CX-4945. CK2 is known to phosphorylate Ser129 on Akt and
this phosphorylation has been reported to contribute to Akt activity (147) which may provide
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an explanation for the decreased phosphorylation of Akt substrates following CX-4945
treatment. Previous reports utilizing CX-4945 demonstrated down-regulation of mTOR
substrates in different cancer lines after a period of 240 minutes (44, 51), and are in
agreement with the phosphoproteomic data presented here. Long term treatment of CX-4945
can result in autophagy, as documented by Kim et al (148). Through phosphorylation of
ULK1 Ser638, mTOR can repress autophagy activation (149), and given that ULK1 Ser638
decreased in phosphorylation after 60 minutes of CX-4945 treatment, the possibility for a
CK2-independent activation of autophagy exists with CX-4945 treatment. Another
interesting phosphorylation site that may be attributable to mTOR activity is EIF5B Ser214,
which showed drastic de-phosphorylation in response to CX-4945 but displays specificity
determinants for CK2. A recent study investigating the phosphoproteome in cells treated with
rapamycin for 2 hours found decreased phosphorylation of EIF5B Ser214, suggesting this
site is a target of mTOR (150). This information raises speculation about the promiscuity of
CX-4945 in cultured human cells, although IC50 values for kinases in the PI3K/Akt pathway
and mTOR that were assayed in vitro were more than 500 times higher than for CK2 (44).
Phosphorylation sites that showed an increase in response to CX-4945 treatment were
attributed to CDK1 and CDK2 kinases. These results are interesting considering that CK2 is
known to phosphorylate Cyclin H in the Cyclin-dependent kinase (CDK) Activating
Complex (CAK) to regulate the activity of this complex (151), which is required for cell
cycle progression through phosphorylation of CDK1 and CDK2 at Thr160/161 (reviewed in
(152)). Inhibition of CK2 would suggest a decrease in CAK activity and therefore a decrease
in CDK1 and CDK2 activity. One plausible consideration is the activity of phosphatase
cdc25C, which can remove inhibitory phosphorylation at Thr14 and Tyr15 (reviewed in
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(153)). Phosphorylation of cdc25C by CK2 at Thr236 results in delayed cytoplasmic-tonuclear transfer of cdc25C, and inhibition of CK2 in vivo results in enhanced nuclear
localization (154), consistent with the suggestion that treatment with CX-4945 inhibits CK2
phosphorylation of cdc25C, enabling increased activity towards the removal of inhibitor
phosphorylation on CDK1 and CDK2. More recent experiments investigating cdc25C
expression levels determined that long-term treatment with CK2 inhibitors actually decreases
the levels of cdc25C and CDK1 (155). Given the short period of time in which HeLa cells are
treated with CX-4945 in this phosphoproteomic investigation, and the utilization of an
asynchronous population, subtle differences in cell cycle regulation may be more apparent in
comparison to cells that have been treated for extended periods of time with inhibitor.
A topological analysis of biological processes and pathways affected by CX-4945
performed using gene enrichment analysis revealed widespread impact on the
phosphoproteome. The enrichment of terms from biological processes derived from
phosphorylation sites which increased were nuclear transport, RNA splicing, negative cell
cycle regulation, apoptotic execution and microtubule regulation. Not surprisingly, CK2 is
known to oppose apoptosis, given that it can translocate to the nucleus following DNA
damage (37) and overexpression of CK2α can promote resistance to TRAIL-induced
apoptosis (34, 156, 157). The large number of phosphorylation sites that increase on proteins
enriched in these pathways can be interpreted as an extensive cellular response to CX-4945,
attributable to the inhibition of not only CK2 but through the up-regulation and de-regulation
of kinases in response to CX-4945.
Phosphorylation sites that decreased were located on proteins involved in mRNA
splicing, mTOR signaling, cytoskeletal organization, chromosome maintenance and nuclear
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envelope formation. It is interesting to note that a recent report demonstrated that CX-4945
regulated mRNA splicing independent of CK2 inhibition and that this could be attributed to
the inhibition of Clk (Cdc2-like-kinase) kinases (158), although CK2 is known to
phosphorylate and regulate the activity of RNA splicing activator RNPS1 (159) and has a
large number of in vitro proteins that are involved in splicing (160). The enrichment of
processes specific to proteins identified as CK2 substrates that decreased in response to CX4945 was divergent from the group of phosphorylation sites that decreased overall, with
enrichment in DNA repair and translation processes. CK2 constitutively phosphorylates
several proteins involved in DNA repair, such as XRCC1 (161), XRCC4 (39), and MDC1
(29), which generates binding sites for FHA (Fork-head associated) domains to recruit other
factors to sites of DNA repair. These data collectively suggest that inhibition of CK2 with
CX-4945 in HeLa cells primarily results in drastic de-phopshorylation of proteins involved in
DNA repair and translation, with secondary effects that are putatively CK2-independent with
respect to processes involved with mRNA splicing and mTOR signaling for that matter.
The investigation of CX-4945 using phosphoproteomics in HeLa cells has revealed a
substantial impact of this CK2 inhibitor in the regulation of phosphorylation of protein
involved in broad range of biological processes. Utilizing bioinformatics tools, the
identification of dynamic markers of CK2 activity was achieved; noting that many of these
phosphorylation sites exhibited de-phosphorylation of a greater magnitude than previously
standardized substrates. A number of interesting responses in the phosphoproteome were
elicited, with many of these changes in phosphorylation sites attributed to other kinases,
suggesting a divergence of specificity for CX-4945 in HeLa cells. Taken together these
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findings demonstrate the utility of phosphoproteomics to characterize the effects of a smallmolecule ATP-competitive inhibitor.
3.4

Experimental Methods

3.4.1 Cell Culture, Lysis & Western Blotting for Preliminary 24 Hour CX-4945
Treatment
HeLa Tet-Off cells (Clontech) were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (Corning) containing 10 % FBS, penicillin (100 U/mL) and streptomycin (100
µg/mL) on 10 cm dishes. Cells were treated with 20 µM CX-4945 (MedKoo Biosciences)
from at various intervals from 1 to 24 hours. Media was vacuum-aspirated and cells were
washed with ice cold PBS, followed by lysis on ice [1% octyl-β-D-glucopyranoside (SigmaAldrich), 50 mM Tris (tris(hydroxymethyl)aminomethane) (Bioshop) pH 8.5, 6 M urea
(Sigma-Aldrich), 25 mM β-glycerophosphate (Bioshop), 1 µM okadaic acid (Bioshop), 50
mM sodium fluoride (Sigma-Aldrich), 1 µM microcystin-LR (Cayman Chemical), 10 mM
sodium orthovanadate (Sigma-Aldrich), 5 mM sodium pyrophosphate (Sigma-Aldrich),
pepstatin (10 µg/mL) (Sigma-Aldrich)]. Samples were sonicated 2 x 15 seconds on ice then
spun for 10 minutes at 16,000 x g at 4 °C. The supernatant was retained and protein
concentration was determined using a Bradford assay (Bio-Rad). An equal amount of each
sample (20 µg) was loaded per lane and separated by SDS-PAGE. Proteins were transferred
to PVDF membrane (Millipore) using a wet-transfer apparatus (Bio-Rad) at 400 mA for 60
minutes at 4 °C followed by incubation in blocking buffer (LI-COR Biosciences) for 60
minutes. Primary antibodies were incubated overnight at 4 °C in 3% BSA-TBST or 3% BSAPBST. Antibodies against PARP (9542, Cell Signaling Technologies), γH2AX S139
(ab26350, Abcam), GAPDH (MAB374, Millipore) and pEIF2S2 S2 (YenZym Laboratories,
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raised against ac-pS-GDEMIFDPTMSKC-amide) were used. Secondary antibodies used
were GAR-800 (926-32211), GAM-800 (926-32210), and GAM-680 (926-32220) (LI-COR
Biosciences) in 3% BSA-TBST or 3% BSA-PBST, with incubation for 45 minutes.
Following 3 x 5 minute washes with TBST or PBST, membranes were scanned using an
Odyssey scanner (LI-COR Biosciences) at 700 nm and 800 nm wavelengths. Raw data scans
were loaded into ImageStudioLite v5.2.5 (LI-COR Biosciences) and exported as .TIFF image
files.
3.4.2 SILAC Medium Formulation
SILAC-dropout DMEM (Life Technologies) lacking L-arginine, L-lysine and Lglutamine was supplemented with isotope-encoded L-arginine (13C6) and L-lysine (4,4,5,5D4) (Cambridge Isotope Laboratories Inc.) at respective concentrations of 86.2 mg/L (0.398
mM) and 61.16 mg/L (0.274 mM) to create a “heavy” medium. “Light” medium was created
using the SILAC-dropout DMEM by supplementing with equivalent molar amounts of
unlabeled L-arginine (83.9 mg/L) and L-lysine (60.04 mg/L). All media used for SILAC
studies were supplemented with 10% 10 kDa-dialyzed FBS (Corning), penicillin (100
U/mL), streptomycin (100 mg/mL), L-glutamine (2 mM) (Life Technologies), and L-proline
(400 mg/L) (Cambridge Isotope Laboratories Inc.) in order to prevent arginine to proline
conversion (131, 162). Media was filter-sterilized prior to use for cell culture.
3.4.3 SILAC Incorporation of HeLa Tet-Off Cells
HeLa Tet-Off cells were adapted over a period of 7 days with 3 sub-passages after being
switched to SILAC medium. An aliquot of protein lysate from heavy labeled cells was
precipitated using 6 sample volumes of 10% TCA in acetone (v/v) and digested on-pellet
(refer to Chapter 2.4.7 for digestion procedure). Trypsin-Lys-C (Promega) at 200:1 (w/w)
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was used for the first 4 hour digestion step and Trypsin at 100:1 (Pierce) was used for the
overnight incubation step. Digested peptides were desalted using a C18 StageTip (Empore)
(163). LC-MS/MS parameters for data acquisition followed those presented in Chapter
2.4.10, with data acquisition performed on an Orbitrap Elite mass spectrometer. Raw spectra
were analyzed using MaxQuant v1.5.3.8 (70, 71, 164) and searched against the SwissprotUniprot sequence database (homo sapiens taxon, accessed on December 26, 2015). Samples
were searched using a Multiplicity set to 2, with “heavy” labels selected as Arg6 and Lys4.
Mass tolerances were set to 4.5 ppm for the parent ion mass (MS) and 0.5 Da for the
fragment ion mass (MS/MS). The minimum number of amino acids in a peptide was set to 7,
with a peptide spectrum match (PSM) and protein match set to 1% FDR and protease
selectivity for trypsin/P. A maximum number of 3 missed cleavages was selected. The
number of variable modifications per peptide was 5, with methionine oxidation (+15.9949),
protein N-terminus acetylation (+42.0105), asparagine and glutamine deamidation (+0.9840
Da) selected. Cysteine carbamidomethylation (+ 57.0215) was set as a fixed modification.
Re-Quantify option was turned on. The minimum score for modified peptides was set to 40,
and the decoy-database setting was “Revert.” Output data from MaxQuant was then loaded
into Perseus version 1.5.2.6 (121). The “evidence.txt” file was used to extract information
about peptides that were quantified in MS1 and identified in MS2, from which reverse hits
and contaminants were removed. The heavy and light intensity values from MS1 quantitation
were used to calculate H/L ratios. Two formulae were applied to calculate the incorporation
for each peptide: H/L ratios larger than 1 were calculated with (100 – (1/ratio)*100), and
ratios less than 1 were calculated with (ratio * 100). The median of all incorporation values
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for each individual SILAC pair was calculated and represents the incorporation efficiency for
the labeled amino acids.
3.4.4 CX-4945 Treatment and Lysis of SILAC HeLa Tet-Off Cells
HeLa Tet-Off cells were cultured in heavy or light-labeled SILAC medium. Cells
were maintained in 15 cm cell culture plates until reaching approximately 80% confluence.
Heavy labeled cells were treated with 20 µM CX-4945 (MedKoo Biosciences) for 60, 135,
180 and 240 minutes, with light labeled cells treated with DMSO vehicle. Three 15 cm plates
(representing three independent biological replicates) were harvested for each labeled
population for each time-point. Following treatment, media was vacuum-aspirated and cells
were washed with ice cold PBS, followed by lysis on ice in 750 µL of lysis buffer [1% octylβ-D-glucopyranoside (Sigma-Aldrich), 50 mM Tris (tris(hydroxymethyl)aminomethane)
(Bioshop) pH 8.5, 6 M urea (Sigma-Aldrich), 25 mM β-glycerophosphate (Bioshop), 1 µM
okadaic acid (Bioshop), 50 mM sodium fluoride (Sigma-Aldrich), 1 µM microcystin-LR
(Cayman Chemical), 10 mM sodium orthovanadate (Aldrich), 5 mM sodium pyrophosphate
(Sigma-Aldrich), pepstatin (10 µg/mL) (Sigma-Aldrich)]. Samples were sonicated for 2 x 15
seconds on ice then spun for 10 minutes at 16,000 x g at 4 °C. The supernatant was retained
and protein concentration was determined using a Bradford assay (Bio-Rad). Samples were
frozen at – 80 °C until processing.
3.4.5 Western Blotting of CX-4945 Treated Samples for Phosphoproteomics
An equal amount of each sample (20 µg) was loaded per lane and separated by SDS-PAGE.
Proteins were transferred to PVDF membrane (Millipore) using a wet-transfer apparatus
(Bio-Rad) at 400 mA for 60 minutes at 4 °C followed by block in blocking buffer (LI-COR
Biosciences) for 60 minutes. Primary antibodies were incubated overnight 4 °C in 3% BSA-
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TBST or 3% BSA-PBST. Antibodies against PARP (9542, Cell Signaling Technologies),
γH2AX S139 (ab26350, Abcam), GAPDH (MAB374, Millipore), pATM S1981 (ab81292,
Abcam), hVIN1 (V9131, Sigma) and pEIF2S2 S2 (YenZym Laboratories, raised against acpS-GDEMIFDPTMSKC-amide) were used. Secondary antibodies used were GAR-800 (92632211), GAM-800 (926-32210), and GAM-680 (926-32220) (LI-COR Biosciences) in 3%
BSA-TBST or 3% BSA-PBST, with incubation for 45 minutes. Data was acquired as
previously outlined in Chapter 3.4.1. Lysates derived from unlabeled HeLa Tet-Off cells
treated with staurosporine (2 µM) (LC Laboratories), 20 ng/mL neocarzinostatin (Sigma), or
DMSO (Fisher) for 3 hours were used as controls.
3.4.6 Sample Digestion and Phosphopeptide Enrichment
Prior to sample processing, 2 mg of protein lysate derived from light labeled cells
(DMSO treated) and 2 mg of protein lysate derived from heavy labeled cells (CX-4945
treated) from each respective biological replicate was mixed, resulting in 12 samples.
Samples were then processed using protein precipitation, and digested following the methods
outlined in Chapter 2.4.7 with some alterations. Trypsin-Lys-C (Promega) at 200:1 (w/w)
was used for the first 4 hour digestion step and Trypsin at 100:1 (Pierce) was used for the
overnight incubation step. Phosphopeptides were enriched following the methods outlined in
Chapter 2.4.8.
3.4.7 LC-MS/MS Data Acquisition
Samples were analyzed using an Orbitrap Elite Hybrid Ion Trap-Orbitrap mass spectrometer
using the acquisition parameters and settings previously described in Chapter 2.4.10. Three
biological replicates per time-point were analyzed in technical duplicate, generating a total of
96 raw mass spectra files. Raw mass spectra files were analyzed in MaxQuant version 1.5.3.8
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(70, 71, 164) and searched against the Swissprot-Uniprot sequence database (homo sapiens
taxon, accessed on December 26, 2015). Samples were searched using a Multiplicity set to 2,
with “heavy” labels selected as Arg6 and Lys4. Mass tolerances were set to 4.5 ppm for the
parent ion mass (MS) and 0.5 Da for the fragment ion mass (MS/MS). The minimum number
of amino acids in a peptide was set to 7, with a peptide spectrum match (PSM) and protein
match set to 1% FDR and protease selectivity for trypsin/P. A maximum number of 3 missed
cleavages was selected. The option for second peptide search was selected, as was the use of
“Match Between Runs” for respective pairs of samples between biological replicates, using
the default matching parameters. Raw mass spectra files were defined as separate groups
using the experimental setup option. Cysteine carbamidomethylation (+ 57.0215 Da) was set
as a fixed modification. For phosphopeptide samples, the number of variable modifications
per peptide was 6, with methionine oxidation (+15.9949 Da), protein N-terminus acetylation
(+42.0105 Da), asparagine and glutamine deamidation (+0.9840 Da) and serine, threonine,
and tyrosine phosphorylation (+79.9663) selected. For proteome samples the maximum
number of variable modifications was set to 5, and phosphorylation as a variable
modification was excluded from these samples. The minimum score for modified peptides
was set to 40, and the decoy-database setting was “Revert.” For quantification of protein
groups, unmodified peptides and those with carbamidomethylation, methionine oxidation,
protein N-terminus acetylation or asparagine and glutamine deamidation were included.
Peptides for which the corresponding heavy or light modified peptide were not quantified
were excluded from the protein groups quantitation. Output data from MaxQuant was then
loaded into Perseus version 1.5.2.6 (121). For the analysis of proteome data, the
“proteinGroups.txt” file was first processed to remove entries marked as reverse decoy
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database hits, contaminants, and protein identifications that were only matched to modified
peptides. MaxQuant-generated normalized ratios were utilized, and the log base 2 of the
normalized ratios was calculated for each protein. Proteins were considered identified in each
biological replicate if identified in at least one of two technical replicates. For the analysis of
the phosphoproteome data, the “Phospho (STY)Sites.txt” file was first processed to remove
entries marked as reverse decoy database hit and contaminants, and filtered to only contain
phosphorylation sites with localization probability greater than 0.75. Phosphorylation sites
were expanded in Perseus to obtain information from instances of quantified sites being
derived from singly, doubly and triply-phosphorylated peptides. Rows where no
quantification was present were removed, and phosphorylation sites were considered
quantified in each biological replicate if they were identified in at least one of two technical
replicates.
3.4.8 Data Analysis
A one-sample Student’s t-test with multiple hypothesis correction using Benjamini Hochberg
FDR = 0.05 was used to identify statistically significant phosphorylation sites that responded
to CX-4945 treatment for each respective time-point dataset. A list of all phosphosites
identified with putative upstream kinases was generated using KinomeXplorer (77) following
criteria outlined in Schoof et al. (165) for kinase prediction and filtering, excluding
prediction scores for a phosphorylation site that was less than 1 and predicting only one
kinase per site. Phosphoproteomic and proteomic data were visualized using the ggplot2
package within the R framework (v3.2.3). PHOXTRACK (128) was used to identify kinasesubstrate relationships that are indicative of up or down-regulation of kinases. The
PhosphositePlus database (138, 166) was queried with uploaded mean log2 ratios of
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phosphorylation sites from each time-point dataset. An unweighted Kolmogorov-Smirnov
running sum statistic was calculated for the query list of phosphorylated sites with the
number of permutations set to 10,000 and the minimum number of phosphosites per kinase
set to 3 with, retaining kinase hits which were < 0.25 FDR and the respective information of
the phosphorylation mark with the upstream kinase. To perform gene enrichment analysis,
statistically significant phosphorylation sites across all time-points were grouped together
into three groups: sites which increased greater than log2 ratio 1, sites which decreased
greater than log2 ratio -1, and sites that decreased greater than log2 -1 and were identified as
CK2 phosphorylation sites. Gene identifiers from these phosphorylation sites were queried
with g:Profiler (129), using the following parameters: the minimum and maximum size of
functional category was 5 and 500 respectively, no electronically inferred GO annotations,
only significant hits displayed, hierarchical filtering enabled, minimum size of gene list and
functional category overlap was 2, significance threshold was set to Benjamini Hochberg and
GO biological process, KEGG pathways and Reactome pathways were queried. The output
was saved in generic enrichment map format and loaded into Cytoscape v3.3.0 (167).
Enriched biological processes and pathways were visualized using the EnrichmentMap
v2.1.0 plugin (142), building the network with minimum similarity score of 0.5 and
maximum q-value (FDR adjusted P value) of 0.005 The AutoAnnotate v1.1.0 plugin (168)
was used to generate word-clouds depicting over-represented terms in the biological
processes and pathways that were clustered together in order to summarize terms for each
cluster.
3.5

Supplemental Figures
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Supplemental Figure 3.1 Frequency Distribution of SILAC Arginine and Lysine
Incorporated Peptides.
HeLa cells were adapted in SILAC medium over 7 days with 3 sub-passages. An aliquot of
heavy labeled cells was processed as described in 3.4.3. Distribution is representative of all
arginine and lysine peptides that were quantified. Red vertical line indicates 95%
incorporation. Median incorporation was calculated as 96.47 %.
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Supplemental Figure 3.2 Preliminary Time-Course Treatment of HeLa Cells with 20
µM CX-4945.
HeLa cells were treated for intervals up to 24 hours with CX-4945 followed by lysis. Lysates
were separated by SDS-PAGE, transferred and western blotted using antibodies against
PARP, GAPDH, γH2AX and phospho-EIF2S2. Refer to 3.4.1 for methods.
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Supplemental Figure 3.3 Biological Replicate 1 of SILAC Labeled Cells Treated with
CX-4945 and Analyzed by LC-MS/MS.
Heavy labeled HeLa cells were treated with 20 µM CX-4945 and light labeled cells were
treated with DMSO for indicated times. HeLa cells treated with staurosporine (STS) or
neocarzinostatin (NCS) served as positive controls. Refer to 3.4.5 for methods.
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Supplemental Figure 3.4 Biological Replicate 2 of SILAC Labeled Cells Treated with
CX-4945 and Analyzed by LC-MS/MS.
Heavy labeled HeLa cells were treated with 20 µM CX-4945 and light labeled cells were
treated with DMSO for indicated times. HeLa cells treated with staurosporine (STS) or
neocarzinostatin (NCS) served as positive controls. Refer to 3.4.5 for methods.
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Supplemental Figure 3.5 Biological Replicate 3 of SILAC Labeled Cells Treated with
CX-4945 and Analyzed by LC-MS/MS.
Heavy labeled HeLa cells were treated with 20 µM CX-4945 and light labeled cells were
treated with DMSO for indicated times. HeLa cells treated with staurosporine (STS) or
neocarzinostatin (NCS) served as positive controls. Refer to 3.4.5 for methods.
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Supplemental Figure 3.6 Frequency Distribution of Phosphorylation Site Mean Log2
Ratio In HeLa Cells Treated with CX-4945 for 60 Minutes.
The mean log2 ratio of three biological replicates for each site identified and quantified is
represented in this frequency distribution of all quantified sites from HeLa cells treated with
20 µM CX-4945 for 60 minutes. Numbers correspond to sites down or up-regulated in Figure
3.2 C. Coloured arrows correspond to increasing, decreasing or decreasing CK2 sites.
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Supplemental Figure 3.7 Frequency Distributino of Phosphorylation Site Mean Log2
Ratio In HeLa Cells Treated with CX-4945 for 135 Minutes.
The mean log2 ratio of three biological replicates for each site identified and quantified is
represented in this frequency distribution of all quantified sites from HeLa cells treated with
20 µM CX-4945 for 135 minutes. Numbers correspond to sites down or up-regulated in
Figure 3.2 C. Coloured arrows correspond to increasing, decreasing or decreasing CK2 sites.
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Supplemental Figure 3.8 Frequency Distribution of Phosphorylation Site Mean Log2
Ratio In HeLa Cells Treated with CX-4945 for 180 Minutes.
The mean log2 ratio of three biological replicates for each site identified and quantified is
represented in this frequency distribution of all quantified sites from HeLa cells treated with
20 µM CX-4945 for 180 minutes. Numbers correspond to sites down or up-regulated in
Figure 3.2 C. Coloured arrows correspond to increasing, decreasing or decreasing CK2 sites.
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Supplemental Figure 3.9 Frequency Distribution of Phosphorylation Site Mean Log2
Ratio in HeLa Cells Treated with CX-4945 for 240 Minutes.
The mean log2 ratio of three biological replicates for each site identified and quantified is
represented in this frequency distribution of all quantified sites from HeLa cells treated with
20 µM CX-4945 for 240 minutes. Numbers correspond to sites down or up-regulated in
Figure 3.2 C. Coloured arrows correspond to increasing, decreasing or decreasing CK2 sites.
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Supplemental Figure 3.10 Frequency Distribution of Protein Mean Log2 Ratio in HeLa
Cells Treated with CX-4945 for 60 Minutes.
The mean log2 ratio of three biological replicates for each protein identified and quantified is
represented in this frequency distribution of all quantified proteins from HeLa cells treated
with 20 µM CX-4945 for 60 minutes.
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Supplemental Figure 3.11 Frequency Distribution of Protein Mean Log2 Ratio in HeLa
Cells Treated with CX-4945 for 135 Minutes.
The mean log2 ratio of three biological replicates for each protein identified and quantified is
represented in this frequency distribution of all quantified proteins from HeLa cells treated
with 20 µM CX-4945 for 135 minutes.
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Supplemental Figure 3.12 Frequency Distribution of Protein Mean Log2 Ratio in HeLa
Cells Treated with CX-4945 for 180 Minutes.
The mean log2 ratio of three biological replicates for each protein identified and quantified is
represented in this frequency distribution of all quantified proteins from HeLa cells treated
with 20 µM CX-4945 for 180 minutes.
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Supplemental Figure 3.13 Frequency Distribution of Protein Mean Log2 Ratio in HeLa
Cells Treated with CX-4945 for 240 Minutes.
The mean log2 ratio of three biological replicates for each protein identified and quantified is
represented in this frequency distribution of all quantified proteins from HeLa cells treated
with 20 µM CX-4945 for 240 minutes.
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Supplemental Figure 3.14 Companion Figure for Figure 3.16
Biological process terms are shown for each node in the network.

102

Supplemental Figure 3.15 Companion Figure for Figure 3.17
Biological process terms are shown for each node in the network.
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4

Chapter 4 – Functional Characterization of the Kinome in Response to CX-4945
Treatment

4.1

Introduction
Protein kinases play a critical role in the regulation of cellular processes through the

phosphorylation of proteins. Historically, strategies have focused on the modulation of
individual phosphorylation sites by individual kinases in distinct cellular contexts. The
emergence of high-throughput phosphoproteomic analyses using mass spectrometry has
enabled the quantitative profiling of the phosphorylation status of thousands of modified sites
in the proteome, and can deliver insights into signaling mechanisms at play in the regulation
of a protein’s function at a network level (56). In such approaches the regulation of kinases
has been studied through the interpretation of the modulation of phosphorylation sites in
distinct cellular contexts or using kinase inhibitors (72, 73). Furthermore, recent
developments in chemical proteomics and mass spectrometry have enabled the enrichment
for kinases to enable profiling of kinase expression and activity at the level of the kinome.
One of the strategies for kinome profiling exploits multiplexed inhibitor beads (MIBs) (82,
83). Multiplexed inhibitor beads consist of sepharose beads conjugated with ATPcompetitive inhibitors that have a broad range of specificity, which enables the capture of a
large number of protein kinases. When coupled with LC-MS/MS, MIBs enable the
quantitative profiling of kinase activity within a cellular context. MIBs can also be applied to
evaluate kinome responses in cells treated with kinase inhibitors and for the systematic
profiling of kinase inhibitor specificity (169).
In an effort to relate responses to CX-4945 that were identified using phosphoproteomics in
the previous chapter, MIB profiling was undertaken to study the effect of CX-4945 at the
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kinome level. Two complementary sample preparation approaches were utilized in order to
profile the kinome of HeLa cells that were treated with CX-4945 for 240 minutes. Utilizing
MIBs enables the quantitative comparison of the amount of kinase bound to the inhibitor
resin, enabling identification of kinases that are up-regulated or down-regulated in response
to inhibitor treatment. Given the enrichment of kinases in comparison to the general
proteome, MIB profiling also enables the identification of phosphorylated kinases, lending
more insight into kinase activity, particularly for the many kinases that are regulated by
phosphorylation (170). Our studies have also incorporated utilization of another CK2
inhibitor “Inhibitor VIII,” which was designed using virtual screening and structure-basedguided methods (87). Inhibitor VIII was exploited for discrimination between CK2dependent or CK2-independent effects of CX-4945 within the CX-4945 dependent
phosphoproteome that was characterized in Chapter 3.
4.2

Results

4.2.1 Multiplexed Inhibitor Bead Profiling Reveals Kinome Perturbation in Response
to CX-4945
In an effort to complement previous phosphoproteomic analysis of CX-4945 in HeLa cells,
multiplexed inhibitor bead (MIB) profiling was performed utilizing two different inhibitorbased MIB resins that have been previously described (171, 172). This workflow consisted of
treating SILAC labeled HeLa cells for 240 minutes with either CX-4945 or DMSO. Three
biological replicates consisting of heavy-labeled cells (CX-4945 treated) and light-labeled
cells (DMSO treated) were profiled using the six-inhibitor mix and the four-inhibitor mix,
resulting in two datasets. A separate experiment consisting of one biological replicate with
heavy-labeled cells (DMSO treated) and light-labeled cells (CX-4945 treated) was profiled
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using the four-inhibitor mix (Figure 4.1). MIB profiling enables the capture of active kinases
to the inhibitor resin, allowing quantitative comparison by LC-MS/MS of labeled peptides
derived from the captured kinases within a given biological context (84). Utilizing these two
different inhibitor resins, profiling of SILAC labeled HeLa cells revealed regulation of kinase
activity in response to CX-4945 treatment, quantifying between 148-217 kinases in separate
analyses (Figure 4.2) in addition to 30-77 phosphorylation sites that were identified on
kinases. The identification of several kinases related to the PI3K/Akt/mTOR pathways that
decreased in activity in response to CX-4945 supported the data previously presented in
chapter 3 which quantified a decrease in phosphorylation on substrates of these kinases
(Figure 4.3, Figure 4.5, Figure 4.7). Kinases such as AKT1 (Akt1), SGK1 (Sgk1), and
RPS6KB1 (p70S6K) decreased approximately 25% (log2 value of -0.4) in response to CX4945, suggesting that inhibition of mTOR occurred with CX-4945 treatment (173-175).
Pyruvate kinase (PKM), which regulates glycolysis and can be controlled by mTOR activity
(176), decreased approximately 3x (log2 value of -1.5). Interestingly, the decrease in CK2
activity (CSNK2A1) was approximately 25%, suggesting that MIB profiling was able to
detect inhibition of CK2 in cells treated with CX-4945. Quantification of CK2 activity was
only detected in samples processed using the six-inhibitor mix. Samples profiled using the
four-inhibitor mix revealed other targets that could be regulated by mTOR, with a decrease in
Akt2 activity of approximately 30%, and an increase in Ulk1 activity of approximately 100%
(Figure 4.7). The change in activity of kinases regulated by mTOR further supports the
notion that CX-4945 treatment results in down-regulation of mTOR.
The capture of kinases using MIBs enabled the identification and quantification of
phosphorylation sites located on kinases that was not previously documented using the
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phosphoproteomics workflow presented in chapter 3, owing largely in part to constraints in
detecting lower-abundance proteins in data-dependent acquisition of a complex lysate
mixture (170). Treatment with CX-4945 resulted in the increase of phosphorylation on
several kinases that are a part of the mitogen activated protein kinase (MAPK) pathway
(Figure 4.4). Thr185/Tyr187 of MAPK1 (ERK2) and Thr202/Tyr204 of MAPK3 (ERK1)
increased in phosphorylation more than 2x, with a downstream target of ERK, RPS6KA1
Ser380 increasing almost 4x in phosphorylation, suggesting activation of the MAPK pathway
after treatment with CX-4945. The increase in MAPK1 phosphorylation sites was
documented using the four-inhibitor MIB beads as well (Figure 4.6). In addition to the
quantification of phosphorylation sites on kinases from MAPK pathway, the quantitation at
the protein level for interleukin-1 receptor-associated kinase (IRAK1) demonstrated a large
increase that was detected using both MIB mixes (Figure 4.3, Figure 4.5). The activity of
IRAK1 has been demonstrated to be required for the phosphorylation of ERK1/2 in the
context of interleukin-mediated signaling (177). Lysates used for proteomic profiling were
analyzed using western blotting, probing against different constituents of the MAPK pathway
using phospho-specific antibodies (Figure 4.9). These results corroborate the quantification
of the phosphorylation sites from kinases captured by the MIBs.
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Figure 4.1 Workflow Overview for Multiplexed Inhibitor Bead Profiling
SILAC-adapted HeLa cells were treated with CX-4945 or DMSO for 240 minutes followed
by lysis. Samples were combined 1:1 based on protein amount and processed using MIBs
that contained either a 6-Inhibitor or 4-Inhibitor mix. Peptides derived from captured kinases
were acquired by LC-MS/MS and raw mass spectra were quantified using MaxQuant
v1.5.3.8.
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Figure 4.2 Summary of Kinases Identified and Quantified by MIB Profiling
Quantitative information from samples processed using the 6-Inhibitor mix was filtered on
the basis of identification and quantification in two out of three biological replicates. For
samples processed using the 4-Inhibitor mix, two out of three biological replicates were
considered separately from the sample in which the light label was treated with CX-4945 and
the heavy label was treated with DMSO. Phosphorylation sites were considered only if
localization exceeded a probability of 0.75.
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Figure 4.3 Quantification of Kinases Using 6-Inhibitor MIBs
The mean log2 (CX-4945/DMSO) ratio is presented from 2 out of 3 biological replicates.
Bars denote standard variation where quantitative information was obtained from 3
biological replicates. Labeled kinases increased > log2 + 0.5 or decreased > log2 - 0.4.
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Figure 4.4 Quantification of Kinase Phosphorylation Sites Using 6-Inhibitor MIBs
Phosphorylation of Ser, Thr, and Tyr residues as a variable modification was included in the
database searching in MaxQuant but excluded in the quantification of protein groups.
Phosphorylation sites that exceeded localization probability of 0.75 are presented. Blank
squares denote values for phosphorylation sites where quantitation was not present in a
biological replicate.
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Figure 4.5 Quantification of Kinases Using 4-Inhibitor MIBs
The mean log2 (CX-4945/DMSO) ratio is presented from 2 out of 3 biological replicates.
Bars denote standard variation where quantitative information was obtained from 3
biological replicates. Labeled kinases increased > log2 + 0.5 or decreased > log2 - 0.4.
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Figure 4.6 Quantification of Kinase Phosphorylation Sites Using 4-Inhibitor MIBs
Phosphorylation of Ser, Thr, and Tyr residues as a variable modification was included in the
database searching in MaxQuant but excluded in the quantification of protein groups.
Phosphorylation sites that exceeded localization probability of 0.75 are presented. Blank
squares denote values for phosphorylation sites where quantitation was not present in a
biological replicate.
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Figure 4.7 Quantification of Kinases Using 4-Inhibitor MIBs in Label Swap
The mean log2 (CX-4945/DMSO) ratio is presented from the label swap, where light HeLa
cells were treated with CX-4945. Labeled kinases increased > log2 + 0.5 or decreased > log2
- 0.4.
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Figure 4.8 Quantification of Kinase Phosphorylation Sites Using 4-Inhibitor MIBs in
Label Swap
Phosphorylation of Ser, Thr, and Tyr residues as a variable modification was included in the
database searching in MaxQuant but excluded in the quantification of protein groups.
Phosphorylation sites that exceeded localization probability of 0.75 are presented.

115
Interestingly, the increase of Tyr15 phosphorylation on CDK1 was detected in response to
CX-4945 from singly phosphorylated peptides that were identified and quantified when
profiling lysates using the six-inhibitor mix (Figure 4.4). The Tyr15 phosphorylation site
was quantified as decreasing in phosphorylation from doubly phosphorylated peptides which
also contain phosphorylation at Thr14. Due to isoform similarity between the CDK-family
kinases, the phosphopeptides which have the localized phosphorylation site match multiple
CDK kinases. Using the four-inhibitor mix, the quantification of Tyr15 from multiply
phosphorylated peptides decreased (Figure 4.6, Figure 4.8)..The quantitation of Tyr15 from
singly phosphorylated peptides was only observed in samples profiled by the four-inhibitor
mix when light-labeled cells were treated with CX-4945 in a label swap experiment. In this
instance only a small increase in phosphorylation was observed in comparison to
quantification obtained when samples were profiled using the six-inhibitor MIBs (Figure 4.6,
Figure 4.8). Given the relative quantitation between singly and doubly phosphorylated
peptides containing phosphorylated Tyr15, and the increase in the singly phosphorylated
form of the Tyr15 site and decrease in the doubly phosphorylated form, this suggests an
overall increase at this phosphorylation site on CDK. The phosphorylation of Tyr15 is
inhibitory to the activity of CDK kinase (178) and can impede the progression from G2 to M
phases of the cell cycle, suggesting that CX-4945 down-regulates the CDK1 activity after
240 minutes of treatment.
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Figure 4.9 MIBs Profiling Reveals Activation of the ERK MAPK Pathway in Response
to CX-4945
Western blot of samples utilized for MIB profiling. 10 µg of lysate was separated by SDSPAGE, transferred to PVDF membrane and probed against antibodies listed to the right of
each panel. R1, R2, R3 and swap denote the four biological replicates that were processed.
Heavy-labeled SILAC HeLa cells from replicates R1-R3 were treated with 20 µM CX-4945
with light-labeled cells being treated with DMSO. In the label swap, treatment and control
samples were switched.
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4.2.2 CX-4945 and Inhibitor VIII Activate MAPK Pathway
To test whether the activation of the MAPK pathway by CX-4945 was independent of
CK2 inhibition, an unrelated small molecule inhibitor of CK2, “Inhibitor VIII” (87) was
utilized in subsequent assays in parallel with CX-4945 treatment. Given that SILAC media
requires growth conditions using FBS that is dialyzed against a 10 kDa membrane in order to
prevent small unlabeled peptides or amino acids from interfering with the adaptation of
heavy labeled amino acids, and that the presence of FBS in cell culture media can induce
phosphorylation of constituents of the MAPK pathway, assays were performed with or
without an overnight serum starve prior to inhibitor treatment. Treatment with 20 µM CX4945 or 15 µM Inhibitor VIII resulted in increased phosphorylation of ERK1/2, which was
observed in tandem with decreased phosphorylation of EIF2S2 Ser2 (Figure 4.10). Following
this observation, samples from this treatment were run against samples from HeLa cells
treated with neocarzinostatin, staurosporine, MG-132 or torin to investigate whether this
increase in phosphorylation was p38 MAPK-dependent, which can become activated in
cellular stress contexts (179, 180) (Figure 4.11), and can be regulated by IRAK1 activity
(177). Interestingly, unlike the treatment with neocarzinostatin or staurosporine, inhibition of
CK2 utilizing CX-4945 or Inhibitor VIII for 240 minutes did not induce p38 MAPK
phosphorylation on Thr180/Tyr182 suggesting a p38 MAPK-independent activation of
ERK1/2. Phosphopeptides from p38 MAPK were detected using MIBs, although only the
singly phosphorylated form with localized site Tyr182 which did not change (Figure 4.4,
Figure 4.8). A differential decrease in phospho-4E-BP1 was also noted between CX-4945
and Inhibitor VIII treated cells.
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Figure 4.10 Activation of the ERK MAPK Pathway in Response to CX-4945 is
Independent of Media Supplementation
Parental HeLa cells were serum starved for 18 hours prior to treatment as noted in the figure.
Cells were then treated with CX-4945 or Inhibitor VIII for 240 minutes. In parallel, HeLa
cells were treated with 1 µM of proteasomal inhibitor MG-132 for 19 hours. All treatments
were performed by delivering drugs that were diluted in cell culture media without FBS
supplementation. Samples presented in this panel were collected in MIBs lysis buffer.
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Figure 4.11 CX-4945 Activation of the ERK1/2 MAPK Pathway is Independent of p38
MAPK
Parental HeLa cells were serum starved for 18 hours prior to treatment as noted in the figure.
Lysates from HeLa cells previously analyzed by western blotting in Figure 4.10 were reanalyzed by western blotting in comparison to extracts derived from HeLa cells treated with
staurosporine (STS), neocarzinostatin (NCS) or Torin1 at indicated concentrations for 4
hours. All treatments were performed by delivering drugs that were diluted in cell culture
media without FBS supplementation. Samples presented in this panel were collected in MIBs
lysis buffer.
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4.2.3 CX-4945 and Inhibitor VIII Display Differential Inhibition of Phospho-4E-BP1
Having observed a decrease in phospho-4E-BP1 (Figure 4.11) and being unable to
confidently identify changes in LC3-II (a marker of autophagy induction, which can be
regulated through mTOR activity towards Ulk1 (181)), HeLa cells that were previously
grown in the presence of FBS were treated with for 240 minutes with CX-4945, Inhibitor
VIII and torin1, followed by sample collection using a lysis buffer containing different
detergents. Lysates were probed with antibodies for components of the PI3K/Akt/mTOR
signaling pathways (Figure 4.12). This experiment confirmed that treating HeLa cells with
CX-4945 led to a decrease of phospho-4E-BP1 signal to a different extent than that seen with
Inhibitor VIII despite both inhibitors decreasing the level of phospho-EIF2S2 to a similar
extent. Torin1 and staurosporine abolished the presence of LC3-I (higher migrating band)
and CX-4945 decreased this to a similar extent in comparison to Inhibitor VIII and DMSO
control. Despite poor resolution of the band by SDS-PAGE because of its high molecular
weight, a decrease in phosphorylation of mTOR at Ser2448 is more noticeable in response to
CX-4945 as compared to Inhibitor VIII treatment.
4.2.4 CX-4945 Induces Rapid Activation of MAPK Pathway and Down-regulation of
PI3K/Akt/mTOR Pathways
Since previous investigation of CX-4945 treated HeLa cells covered time-points that spanned
between 60 and 240 minutes, assays were performed within a window of time which
preceded 60 minutes in order to explore whether CX-4945 effects would be evident. Indeed,
the activation of the MAPK pathway was rapid, occurring within a span of 15 minutes as
evidenced by increases in phosphorylation of ERK1/2 and MEK1/2 (Figure 4.13).
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Interestingly the phosphorylation of p70S6K Thr389 was reduced quickly in comparison to
EIF2S2 Ser2 and Akt Ser129. The phosphorylation of c-Raf Ser338,

Figure 4.12 Differential Inhibition of mTOR Using CX-4945 and Inhibitor VIII
HeLa cells were grown in media supplemented with FBS, followed treated with CX-4945,
Inhibitor VIII, Torin1 or staurosporine for 240 minutes at indicated concentrations. Samples
collected in this panel were collected in a RIPA lysis buffer.
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Figure 4.13 Activation of the ERK MAPK Pathway in Reponse to CX-4945 is Rapid
HeLa cells were serum starved for 18 hours prior to treatment as noted in the figure. Cells
were then treated with CX-4945 for indicated time-points up to 180 minutes. All treatments
were performed delivering drugs that were diluted in cell culture media without FBS
supplementation. Samples collected in this panel were collected in RIPA lysis buffer.
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which contributes to the activity of c-Raf (182, 183), did not change in response to CX-4945
within 180 minutes of treatment. c-Raf activity can also be regulated at Ser259 through
phosphorylation by Akt, which is inhibitory as it can be sequestered by 14-3-3 proteins (184186) and can be de-phosphorylated by protein phosphatase 2A (PP2A) (187). In a follow-up
experiment, HeLa cells were serum starved overnight followed by pre-treatment with or
without PP2A inhibitor okadaic acid (1 µM) for 15 minutes followed by treatment with CX4945 to test if the phosphorylation status at c-Raf Ser259 could be contributing to MEK1/2
and ERK1/2 activity (Figure 4.14). The phosphorylation status at Ser259 of c-Raf did not
change in the presence or absence of okadaic acid when cells were treated with CX-4945,
suggesting that the phosphorylation status of Ser338 and Ser259 on c-Raf is not a
requirement for activation of MEK1/2 and ERK1/2 in response to CX-4945. The induction of
ERK1/2 phosphorylation can be achieved in a span of 10 minutes of treatment with CX-4945
or Inhibitor VIII and is nearly comparable to the induction observed using EGF within the
same time (Supplemental Figure 4.14.1). Treatment with CX-4945 resulted in decreased
phosphorylation of Akt Ser473 and Thr308, with pre-treatment using okadaic acid resulting
in complete reduction of phosphorylation at these sites when treated with CX-4945 in
comparison to cells that did not receive okadaic acid prior to CX-4945.
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Figure 4.14 Activation of ERK MAPK is Independent of c-Raf Ser259
HeLa cells were serum starved for 18 hours prior to treatment as noted in the figure. Cells
were pre-treated with or without 1 µM okadaic acid for 15 minutes prior to treatment with
CX-4945 at indicated time-points. All treatments were performed delivering drugs that were
diluted in cell culture media without FBS supplementation. Samples collected in this panel
were collected in a RIPA lysis buffer.
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4.2.5 CX-4945 and Inhibitor VIII Affect Cell Cycle Regulation
Previous phosphoproteomic analysis suggested an increase in CDK1 and CDK2
activity in response to CX-4945 treatment, while identification of phosphopeptides enriched
from MIB profiling suggested an increase in Tyr15 which results in an inhibition of CDK
activity. To investigate this discrepancy, HeLa cells were arrested in specific phases of the
cell cycle and analyzed using western blotting with antibodies against cell cycle markers in
addition to profiling using flow cytometry (Figure 4.15, Supplemental Figure 4.44.4).
Treatment with 20 µM CX-4945 did not result in an evident increase in Tyr15
phosphorylation on CDK1 in comparison to DMSO after 240 minutes of treatment.
Strikingly, treatment with 15 µM Inhibitor VIII resulted in increase phosphorylation of
histone H3 Ser13 in comparison to either DMSO or CX-4945 within this period of time. This
result is completely reversed upon longer treatment for 22 hours with either inhibitor, with
complete abolishment of phospho-histone H3 Ser10 in cells treated with Inhibitor VIII. The
increase in histone H3 Ser10 phosphorylation and total cyclin B1 suggests a G2/M phase
arrest. Analysis using a two-colour method to analyze cell-cycle phase by flow cytometry
(188) with the same clone for phospho-histone H3 Ser10 confirmed this result (Figure 4.16,
Figure 4.17). Treatment of HeLa cells with CX-4945 for 4 hours results in an increase in G2
specific cells in comparison to DMSO while the mitotic population remains similar. In
contrast, Inhibitor VIII causes a 4x increase in the mitotic population. In agreement with the
western blot analysis, long-term treatment with CX-4945 created a G2/M specific arrest,
although there is a substantial amount of cells that are apoptotic (Figure 4.17). This apoptotic
population is underestimated given the reliance on gating forward scatter and side scatter
profiles of singlet
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Figure 4.15 CX-4945 and Inhibitor VIII Perturb Cell Cycle Regulation
HeLa cells were grown in media supplemented with FBS, followed treated with CX-4945,
Inhibitor VIII, Torin1 or staurosporine for 240 minutes or 22 hours at indicated
concentrations. In parallel HeLa cells were treated with lovastatin, mimosine, thymidine or
nocodazole for 24 hours at indicated concentrations. All treatments were performed by
delivering drugs that were diluted in cell culture media without FBS supplementation.
Samples collected in this panel were collected in a RIPA lysis buffer.
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Figure 4.16 CX-4945 and Inhibitor VIII Exert Differential Effect on Histone H3
Phosphorylation
HeLa cells were grown in media supplemented with FBS, followed by treated with CX-4945,
Inhibitor VIII, Torin1 or staurosporine for 240 minutes. Cells were processed for cell cycle
analysis by flow cytometry, staining with 7-AAD, and antibodies against Ki-67 and phosphohistone H3 Ser10, both conjugated to AlexaFluor-488. Gating was performed on forward and
side scatter profiles to isolate single cells, and samples derived from HeLa cells arrested in
specific phases of the cell cycle were used to appropriately gate cell populations presented.
All treatments were performed delivering drugs that were diluted in cell culture media
without FBS supplementation.
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Figure 4.17 CX-4945 and Inhibitor VIII Result In Divergent Cell Cycle Arrest
HeLa cells were grown in media supplemented with FBS, followed by treated with CX-4945,
Inhibitor VIII, Torin1 or staurosporine for 22 hours. Cells were processed for cell cycle
analysis by flow cytometry, staining with 7-AAD, and antibodies against Ki-67 and phosphohistone H3 Ser10, both conjugated to AlexaFluor-488. Gating was performed on forward and
side scatter profiles to isolate single cells, and samples derived from HeLa cells arrested in
specific phases of the cell cycle were used to appropriately gate cell populations presented.
All treatments were performed delivering drugs that were diluted in cell culture media
without FBS supplementation.
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cells within this assay which can occlude cells that have changed in shape and size as a result
of undergoing apoptosis. Using a flow cytometry assay that directly measures cell viability
using 7-AAD and annexin-V staining, 51% and 34% of HeLa cells treated with 20 µM CX4945 or 15 µM Inhibitor VIII respectively remain viable (Supplemental Figure 4.24.2).
4.3

Discussion
Investigation of the phosphoproteome presented previously in this thesis revealed a

dynamic regulation of phosphoproteins in response to CX-4945 treatment in HeLa cells,
suggesting a dynamic change in the activity of protein kinases responsible for
phosphorylation of these substrates. MIBs allow the quantitative profiling of the kinome and
have been utilized to study the effects of small-molecule ATP-competitive inhibition of
kinases (84). To corroborate the putative regulation of kinases, we utilized two different
inhibitor combinations for MIB profiling in order to monitor the kinase activity in extracts
from HeLa cells treated with CX-4945 for 240 minutes.
The identification of the down-regulation of activity for kinases in the
PI3K/Akt/mTOR pathways such as Sgk1, Akt and RPS6KB1 and the up-regulation of Ulk1
activity validates the phosphoproteomic data presented earlier. The down-regulation of Sgk1,
Akt and RPS6KB1 which are downstream of mTOR is in agreement with the literature which
has identified CX-4945 treatment affecting Akt and mTOR activity (51, 54, 189). By
comparison, the activity of mTOR as detected by MIB profiling did not appear to change
using either MIB mix. One constituent that is regulated by mTOR, PKM, decreased in
activity in response to CX-4945 and highlights a previously uncharacterized effect of this
inhibitor with dramatic implications on metabolic regulation of glycolysis. CK2 has been
implicated in regulation of metabolism, through the phosphorylation of phosphoglucose
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isomerase (PGI) which is involved in glycolysis (190). A role in the regulation of the
PI3K/Akt/mTOR pathways by CK2 has been previously implicated through the
phosphorylation of phosphatase and tensin homolog (PTEN), which can stabilize the
phosphatase preventing activity that is inhibitory towards the PI3K/Akt axis (191, 192). In a
different investigation by So et al., treatment of cells with CX-4945 for extended periods of
time in PC9 cells induced autophagy (193). LC3 can be used as a marker for autophagy, and
when conjugated to phosphatidylethanolamine (denoted as LC3-II), it can be detected as a
lower migrating band using SDS-PAGE/immuno-blotting (194). In contrast to the findings
by So et al., experiments performed here used HeLa cells with initial western blotting failing
to yield a clear difference in accumulation of LC3-II. When samples were collected using a
denaturing buffer with NP-40 detergent, there was no apparent difference in LC3-II among
samples treated with CX-4945, Inhibitor VIII or torin1. The presence of LC3-I (the higher
migrating band) was slightly reduced with CX-4945 treatment in comparison to Inhibitor
VIII and was comparable to treatment with torin1 or staurosporine. This may suggest an
activation of autophagy as a result of mTOR inhibition, given that MIB profiling identified
an increase in Ulk1 activity. Taking these details into perspective, it is interesting that when
western blotting was performed using antibodies against phospho-4E-BP1 in lysates derived
from HeLa cells that were treated with two unrelated inhibitors of CK2, a differential effect
in the level of phosphorylation was noted between CX-4945 and Inhibitor VIII treatment.
Both CK2 inhibitors reduced the phosphorylation level of EIF2S2, confirming inhibition of
CK2 by both inhibitors and suggesting a potential divergence in the specificity between these
two inhibitors when investigating the PI3K/Akt/mTOR pathway.
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The intersection of the PI3K/Akt/mTOR and MAPK pathways has been previously proposed
(as reviewed in (195)). Treatment with CX-4945 resulted in the activation of kinases that
comprise the ERK MAPK pathway, with increased phosphorylation of ERK1/2, MEK1/2,
and p90-RSK as quantified using MIB profiling. CK2-dependent inhibition is suggested as a
potential mechanism given that two unrelated inhibitors of CK2 result in increased
phosphorylation of ERK1/2 Thr202/Tyr204. This effect was determined to be independent of
p38 MAPK activation, as treatment with either CK2 inhibitor did not result in
phosphorylation of p38 MAPK. Interestingly, the activity of IRAK1 increased in response to
CX-4945, and it has been documented that IRAK1 activation can lead to p38 MAPK
activation dependent on Ras activation (196). The phosphorylation status of Ser259 on c-Raf
did not change in this context, suggesting that the intersection of the PI3K/Akt pathway does
not regulate this arm of the MAPK pathway. The activity of IRAK1 upstream of Ras
suggests this pathway could still be activating c-Raf, given that other phosphorylation sites
on c-Raf that modulate activity were not profiled. Previous investigation of CK2 in
glioblastoma cells highlighted the activation of ERK in response to CK2 knockdown in the
presence or absence of neocarzinostatin, although the presence of neocarzinostatin
substantially enchanced ERK phosphorylation (197). The results presented here support the
activation of the ERK MAPK pathway when cells are treated with CX-4945 or Inhibitor
VIII, suggesting a CK2-dependent role in this manner. In contrast to this, more recent studies
conducted in melanoma cell lines identified a CK2-dependent role for proteasomal
degradation of dual specificity phosphatase-6 (DUSP6), which can reverse the activating
phosphorylation on ERK mediated by MEK (198). Knock-down of CK2α resulted in
increased levels of DUSP6, while high expression of CK2α maintained ERK
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phosphorylation. A cell-line dependent effect may be plausible for the differences
documented in terms of ERK phosphorylation, warranting further investigation. Despite
apparent cell type specific contexts, these observations all suggest that CK2 can modulate the
ERK MAPK pathway.
The identification of CDK phosphorylation at Tyr15 using MIB profiling suggested
that in response to CX-4945 treatment HeLa cells undergo cell cycle arrest. The
phosphorylation at Tyr15 is well known to inhibit the activity of CDK1 (178). In contrast, the
phosphoproteomic investigation revealed that CDK1 and CDK2 substrates increased in
phosphorylation in response to CX-4945 suggesting a progression in cell cycle from G2 to M
phase. Western blotting and flow cytometry analysis were performed to investigate this
difference. In agreement with the existing literature, CX-4945 treatment resulted in a G2/M
accumulation during longer periods of treatment (44, 45). Shorter treatment of 240 minutes
saw an increase in the G2 population in comparison to DMSO, suggesting cell cycle arrest
occurred rapidly. These effects were not evident by western blotting at shorter time-points
given that the markers used were specific for identifying the mitotic phase. Remarkably,
treatment with Inhibitor VIII increased the phosphorylation of histone H3 Ser10 at 240
minutes but abolished it completely at 22 hours. One possible hypothesis is that treatment
with this inhibitor drives cell cycle progression into mitosis, given that reports of histone H3
Ser10 phosphorylation as a result MAPK activation have been documented (199). The
increase in mitotic phase cells was not as pronounced with CX-4945 treatment, and given the
complete abolishment of histone H3 Ser10 phosphorylation at 22 hours of treatment with
Inhibitor VIII, the specific reason for why histone H3 Ser10 phosphorylation occurs is
difficult to reconcile without further investigation. Inhibitor VIII may exert a stimulatory
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effect upon the kinase responsible for phosphorylation of histone H3 Ser10, Aurora B kinase
(200, 201), or it may antagonize phosphatase activity towards this site (202, 203). This
previously undocumented divergence between Inhibitor VIII and CX-4945 further calls into
question the specificity of these CK2 inhibitors given differential outcomes in the
phosphorylation status of proteins involved in distinct cellular processes.
Kinome profiling using MIBs enabled the characterization of kinase activity and
validation of phosphoproteomic profiling of HeLa cells treated with CX-4945. A broad effect
on kinase activity was documented, corroborating changes in the activity of kinases as
inferred by phosphoproteomic analysis of HeLa cells treated with CX-4945 in earlier
investigations in this thesis. Taken together, the analysis of the kinome and phosphoproteome
identify CK2-dependent and CK2-independent effects in HeLa cells. Utilization of a different
CK2 inhibitor further substantiates CK2-independent effects of CX-4945, as suggested by the
incomplete overlap between the cellular effects of CX-4945 and Inhibitor VIII. These
revelations call into question the utility of CX-4945 as an inhibitor of CK2 to study putative
CK2-dependent processes in cells and warrant future studies to characterize putative CK2independent effects.
4.4

Experimental Methods

4.4.1 Cell Culture and Lysis for Multiplexed Inhibitor Bead Profiling
SILAC-dropout DMEM (Life Technologies) supplemented with light and heavy isotopeencoded L-arginine and L-lysine was prepared as previously described in Chapter 3.4.2.
HeLa Tet-Off cells that were previously adapted in SILAC media were grown in 15 cm
dishes. Three biological replicates (consisting of three independent cell culture plates
harvested on the same day) of heavy labeled cells were treated with 20 µM CX-4945
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(MedKoo Biosciences) for 240 minutes with light labeled cells being treated with DMSO. In
a “label-swap experiment” one biological replicate was used where the heavy labeled cells
were treated with DMSO and the light labeled cells were treated with 20 µM CX-4945. Cells
were rinsed with ice-cold PBS and lysed in MIB lysis buffer [0.5% Triton X-100 (Sigma), 50
mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) pH 7.5 (Bioshop), 1 mM
EDTA, 1 mM EGTA, 10 mM sodium fluoride, 1 µM microcystin-LR, 2.5 mM sodium
orthovanadate, pepstatin (2.0 µg/mL), 0.2 mM phenylmethylsulfonyl fluoride (PMSF),
leupeptin (20 µg/mL), aprotinin (4 µg/mL), and 1x phosphatase inhibitor cocktail 2 & 3
(Sigma P5726, P0044)]. Samples were sonicated for 3 x 10 seconds on ice then spun for 10
minutes at 16,000 x g at 4 °C. The supernatant was collected and clarified once more using a
0.2 µm syringe filter and protein concentration was determined by Bradford Assay (Bio Rad)
before being stored at -80 °C until further processing. Aliquots of samples were diluted in
sample loading buffer and 10 µg of sample was loaded per lane and separated by SDSPAGE. Proteins were transferred to PVDF membrane (Millipore) using a wet-transfer
apparatus (Bio-Rad) at 400 mA for 60 minutes at 4 °C followed by block in blocking buffer
(LI-COR Biosciences) for 60 minutes. Primary antibodies were incubated overnight at 4 °C
in 3% BSA-TBST or 3% BSA-PBST. Antibodies against GAPDH (MAB374, Millipore) and
pEIF2S2 S2 (YenZym Laboratories, raised against ac-pS-GDEMIFDPTMSKC-amide) were
used. Secondary antibodies used were GAR-800 (926-32211), GAM-800 (926-32210), and
GAM-680 (926-32220) (LI-COR Biosciences) in 3% BSA-TBST or 3% BSA-PBST, with
incubation for 45 minutes. Membranes were scanned using an Odyssey scanner (LI-COR
Biosciences) at 700 nm and 800 nm wavelengths. Raw data scans were loaded into
ImageStudioLite v5.2.5 (LI-COR Biosciences) and exported as .TIFF image files.
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4.4.2 Multiplexed Inhibitor Bead Profiling Using a 6-Inhibitor Mix
MIB profiling of SILAC-labelled HeLa cells treated with CX-4945 was adapted from the
protocol that was previously described by Qin et al (171). The MIB mix utilized was a
generous gift from Dr. Lee M. Graves at the University of North Carolina, Chapel Hill, NC,
and consisted of six kinase inhibitors each conjugated to ECH sepharose 4B: Shokat (204),
PP58 (205, 206), VI16832 (83), Ctx-0294885 (207), purvalanol-B (208), and pan-Akt
inhibitor UNC21474 (171). Chemical structures of these kinase inhibitors are displayed in
Supplemental Figure 4.5. Equivalent amounts (2.5 mg) of heavy and light SILAC lysates
were brought to 1M NaCl and equalized for volume prior to mixing. Samples were first
passed over a column (Bio-Rad) containing ECH sepharose 4B, followed by passage over a
column containing MIBs. MIB columns were then washed with 5 mL MIB lysis buffer
containing 1M NaCl, followed by 5 mL MIB lysis buffer and 0.5 mL MIB lysis buffer
containing 0.1% (w/v) SDS. Captured proteins were eluted twice with 0.5 mL [0.5% (w/v)
SDS, 1% beta-mercaptoethanol, 100 mM Tris-HCl pH 6.8] by incubating at 95 °C for 15
minutes. Samples were then reduced with 5 mM DTT (Sigma) for 25 minutes at 60 °C,
alkylated with 20 mM IAA (Sigma) for 30 minutes at room temperature in the dark and
quenched with the addition of 10 mM DTT. Samples were then concentrated using 0.5 mL
10 kDa-cutoff spin filters (Millipore) and reduced to approximately 100 µL of volume.
Samples were precipitated following chloroform (Sigma) and methanol (Fisher) extraction,
using methanol, chloroform and water at a ratio of 4:1, 1:1 and 3:1 respectively to sample
volume. Precipitated protein was pelleted by centrifugation at 16, 000 x g for 10 minutes
followed by two washes with 0.5 mL of methanol. Pellets were digested using 1 µg trypsinLys-C (Promega) for 4 hours at 37 °C and topped up with 1 µg trypsin (Pierce) for overnight
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digestion in 50 mM ammonium bicarbonate. Samples were then desalted using C18
StageTips, concentrated in a SpeedVac vacuum centrifuge and stored at -80 °C until LCMS/MS analysis.
4.4.3 Multiplexed Inhibitor Bead Profiling Using a 4-Inhibitor Mix
MIB profiling of SILAC-labelled HeLa cells treated with CX-4945 was performed as
previously described in Kurimchak et al. (172) and followed procedures similar to that used
with the 6-Inhibitor mix. The MIB mix utilized was a generous gift from Dr. James S.
Duncan at Fox Chase Cancer Center, Philadelphia, PA, and consisted of four inhibitors: PP58
(205, 206), VI16832 (83), Ctx-0294885 (207) and purvalanol-B (208). Heavy and light
SILAC-labelled lysates (3-5 mg) were brought to 1M NaCl and equalized for volume prior to
mixing. Samples were first passed over a column (Bio-Rad) containing beads conjugated
with inhibitors PP-58, VI-16832 and purvalanol-B, followed by passage over a second
column containing Ctx-0294885. MIB columns were then washed separately with 2 x 10 mL
MIB lysis buffer containing 1M NaCl, followed by 10 mL MIB lysis buffer. Samples were
then eluted from each column and combined prior to concentration. All subsequent steps in
sample preparation followed the 6-Inhibitor mix procedure outlined in section 4.4.2.
4.4.4 LC-MS/MS Analysis of Samples Profiled by Multiplexed Inhibitor Beads
Samples were analyzed using an Orbitrap Elite Hybrid Ion Trap-Orbitrap mass spectrometer
using the acquisition parameters and settings previously described in Chapter 2.4.10.
Biological replicates were each analyzed in technical duplicate. Raw mass spectra files were
analyzed in MaxQuant version 1.5.3.8 (70, 71, 164) and searched against the SwissprotUniprot sequence database (homo sapiens taxon, accessed on December 26, 2015). Samples
were searched using a Multiplicity set to 2, with “heavy” labels selected as Arg6 and Lys4.
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Mass tolerances were set to 4.5 ppm for the parent ion mass (MS) and 0.5 Da for the
fragment ion mass (MS/MS). The minimum number of amino acids in a peptide was set to 7,
with a peptide spectrum match (PSM) and protein match set to 1% FDR and protease
selectivity for trypsin/P. A maximum number of 3 missed cleavages was selected. The option
for second peptide search was selected, as was the use of “Match Between Runs” for
respective pairs of samples between biological replicates, using the default matching
parameters. Raw mass spectra files were defined as separate groups using the experimental
setup option. Cysteine carbamidomethylation (+ 57.0215 Da) was set as a fixed modification.
The number of variable modifications per peptide was 5, with methionine oxidation
(+15.9949 Da), protein N-terminus acetylation (+42.0105 Da), asparagine and glutamine
deamidation (+0.9840 Da) and serine, threonine, and tyrosine phosphorylation (+79.9663)
selected. The minimum score for modified peptides was set to 40, and the decoy-database
setting was “Revert.” For quantitation of protein groups, unmodified peptides and those with
carbamidomethylation, methionine oxidation, protein N-terminus acetylation or asparagine
and glutamine deamidation were included. Peptides for which the corresponding heavy or
light modified peptide was not quantified were excluded from the protein groups
quantitation. Output data from MaxQuant was then loaded into Perseus version 1.5.2.6 (121).
For the analysis of proteome data, the “proteinGroups.txt” file was first processed to remove
entries marked as reverse decoy database hits, contaminants, and protein identifications that
were only matched to modified peptides. MaxQuant-generated normalized ratios were
utilized, and the log base 2 of the normalized ratios was calculated for each protein. Proteins
were considered identified in each biological replicate if identified in at least one of two
technical replicates. For the analysis of the phosphoproteome data, the “Phospho
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(STY)Sites.txt” file was first processed to remove entries marked as reverse decoy database
hit and contaminants, and filtered to only contain phosphorylation sites with localization
probability greater than 0.75. Phosphorylation sites were expanded in Perseus to obtain
information from instances of quantified sites being derived from singly, doubly and triplyphosphorylated peptides. Rows where no quantification was present were removed, and
phosphorylation sites were considered quantified in each biological replicate if they were
identified in at least one of two technical replicates.
4.4.5 Cell Culture and Lysis for Analysis of mTOR/Akt and MAPK Pathways
HeLa Tet-Off cells (Clontech) were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (Corning) containing 10 % FBS, penicillin (100 U/mL) and streptomycin (100
µg/mL) on 10 cm dishes or in 6-well plates. Cells were either grown in media containing
10% FBS or were serum starved for 18 hours prior to treatment with inhibitors. Cells were
treated with 20 µM CX-4945 (MedKoo Biosciences), 15 µM Inhibitor VIII (Calbiochem),
0.25 µM Torin1 (Selleckchem), 1 µM MG-132 (Sigma), 20 ng/mL neocarzinostatin (Sigma),
2 µM staurosporine (LC Laboratories) or DMSO diluted in media without FBS for indicated
time-points. Cells were rinsed with PBS on ice prior to lysis. For experiments used to
generate Figures 4.10-4.11, HeLa cells were lysed in MIB lysis buffer that is described in
section 4.4.1. For all remaining experiments, HeLa cells were lysed in a RIPA lysis buffer
[1% NP-40 Alternative (Calbiochem), 50 mM Tris pH 7.5, 150 mM sodium chloride 0.5%
sodium deoxycholate (Sigma), 0.2% SDS, 1 mM EDTA, 25 mM β-glycerophosphate, 1 µM
okadaic acid, 50 mM sodium fluoride, 1 µM microcystin-LR, 10 mM sodium orthovanadate,
5 mM sodium pyrophosphate, pepstatin (10 µg/mL), 1 mM phenylmethylsulfonyl fluoride
(PMSF), leupeptin (100 µg/mL), and aprotinin (20 µg/mL)]. Samples were sonicated for 2 x
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15 seconds on ice then spun for 10 minutes at 16,000 x g at 4 °C, upon which the supernatant
was retained and protein concentration was determined using a BCA assay (Pierce). Samples
(10 µg each) were separated by SDS-PAGE and transferred to PVDF membranes for Western
blotting using procedures outlined in Chapter 4.4.1. Antibodies against phospho-p90RSK
S380 (9335), p90RSK (9355), phospho-ERK1/2 T202/Y204 (9106), ERK (9102), phosphoMEK1/2 S217/221 (9154), MEK1/2 (4694), phospho-p38 MAPK T180/Y182 (9216), p38
MAPK (8690), phospho-Akt T308 (13038), phospho-Akt S473 (4060), phospho-c-Raf S338
(9427), phospho-c-Raf S259 (9421), phospho-mTOR S2448 (5536), mTOR (2983), LC3B
(3868), phospho-Raptor S792 (2089), phospho-Ulk1 S638 (14205), p70S6K T389 (9234),
PARP (9542), phospho-4E-BP1 T37/46 (2855) (all from Cell Signaling Technologies),
hVIN1 (V9131, Sigma), γH2AX S139 (ab26350, Abcam), phospho-Akt S129 (ab133458,
Abcam), GAPDH (MAB374, Millipore), and phospho-EIF2S2 S2 (YenZym Laboratories,
raised against ac-pS-GDEMIFDPTMSKC-amide) were used.
4.4.6 Cell Culture and Sample Preparation for Cell Cycle Analysis using Flow
Cytometry and Western Blotting
HeLa Tet-Off cells (Clontech) were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (Corning) containing 10 % FBS, penicillin (100 U/mL) and streptomycin (100
µg/mL) on 10 cm dishes. Cells were treated with 20 µM CX-4945 (MedKoo Biosciences), 15
µM Casein Kinase II Inhibitor VIII (Calbiochem), 0.25 µM Torin1 (Selleckchem) or DMSO
for 240 minutes or 22 hours. In parallel, cells were treated with 40 µM lovastatin (SigmaAldrich), 400 µM mimosine (Sigma-Aldrich), 2 mM thymidine (Sigma-Aldrich), nocodazole
(0.4 µg/mL) (Sigma-Aldrich) or were serum-starved for 24 hours to generate arrested
populations to aid in the setting of cell-cycle specific gated populations for flow cytometry
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and for the comparison by Western blotting using cell-cycle markers. After treatment, media
was retained and adherent cells were washed with PBS, then incubated with 0.25% trypsin,
0.02% EDTA solution at 37 °C to lift the cells. Cells were suspended in collected media,
centrifuged at 100 x g then suspended in fresh serum-free DMEM. An aliquot was stained
with 0.08% trypan blue solution (Sigma-Aldrich) and the concentration of cells was
determined using a hemocytometer. Aliquots of 1 million cells were centrifuged at 100 x g
and washed with PBS. For Western blotting, cell pellets were lysed in 300 µL lysis buffer
[1% NP-40 Alternative (Calbiochem), 50 mM Tris pH 7.5, 150 mM sodium chloride 0.5%
sodium deoxycholate (Sigma), 0.2% SDS, 1 mM EDTA, 25 mM β-glycerophosphate, 1 µM
okadaic acid, 50 mM sodium fluoride, 1 µM microcystin-LR, 10 mM sodium orthovanadate,
5 mM sodium pyrophosphate, pepstatin (10 µg/mL), 1 mM phenylmethylsulfonyl fluoride
(PMSF), leupeptin (100 µg/mL), and aprotinin (20 µg/mL)]. Samples were sonicated for 2 x
15 seconds on ice then spun for 10 minutes at 16,000 x g at 4 °C, upon which the supernatant
was retained and protein concentration was determined using a BCA assay (Pierce). Samples
(10 µg each) were separated by SDS-PAGE and transferred to PVDF membranes for Western
blotting

using

procedures

outlined

in

Chapter

4.4.1.

Antibodies against phospho-histone H3 S10 (9542), histone H3 (9715), cyclin B1 (12231), phospho-cdc2 Y15 (4539), phospho-4EBP1 T37/46 (2855) (all from Cell Signaling
Technologies), γH2AX S139 (ab26350, Abcam), GAPDH (MAB374, Millipore), and
phospho-EIF2S2 S2 (YenZym Laboratories, raised against ac-pS-GDEMIFDPTMSKCamide) were used. For flow cytometry analysis, samples were processed as previously
described in Vignon et al. (188) with some modifications. Cell pellets were suspended in 1
mL PBS and added drop-wise to 5 mL of ice cold 95% ethanol with agitation between drop-

141
wise addition then fixed overnight at – 20 °C. Samples were centrifuged at 500 x g for 5
minutes at room temperature, followed by aspiration of ethanol and suspended in PBS before
being transferred to FACS tubes. Samples were then washed twice with 3 mL PBS, followed
by two washes with 1 mL 0.25% Triton X-100, 1% FBS in PBS (PFT). Samples were stained
in 200 µL of PFT for 30 minutes in the dark, after being mixed with 15 µg of 7aminoactinomycin (7-AAD) (A1310, Thermo Scientific), 3 µL of anti-phospho-histone H3
Ser10 conjugated to AlexaFluor-488 (3465, Cell Signaling Technology), and 3 µL of antiKi67 conjugated to AlexaFluor-488 (11882, Cell Signaling Technology). Single stain and
iso-type controls were processed in parallel. Samples were then washed twice with 1 mL PFT
and once with 1mL PBS. Cells were analyzed on a Becton Dickinson FACSCanto cytometer
using FACSDiva software, acquiring 10,000 cell events per sample. Data generated were
analyzed using FLOWJo software v10.2 (FLOWJo, LLC, Ashland, Oregon), gating
populations according to forward and side scatter profiles and setting cell-cycle specific
populations according to positive control populations arrested in specific phases of the cell
cycle.
4.4.7 Cell Culture and Sample Preparation for Cell Viability Analysis using Flow
Cytometry
HeLa Tet-Off cells (Clontech) were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (Corning) containing 10 % FBS, penicillin (100 U/mL) and streptomycin (100
µg/mL) on 10 cm dishes. Cells were treated with 20 µM CX-4945, 15 µM Casein Kinase II
Inhibitor VIII, or DMSO for 240 minutes or 22 hours. In parallel, cells were treated with 2
µM staurosporine as a positive control for gating live and dead cell populations. After
treatment, media was retained and adherent cells were washed with PBS, then incubated with
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0.25% trypsin, 0.02% EDTA solution at 37 °C to lift the cells. Cells were suspended in
collected media, centrifuged at 500 x g then suspended in warm 5% FBS in PBS. An aliquot
was stained with 0.08% trypan blue solution (Sigma-Aldrich) and the concentration of cells
was determined using a hemocytometer. 100,000 cells were aliquoted into FACS tubes,
centrifuged at 100 x g and suspended in 200 µL Annexin V binding buffer (Biolegend). 4 µL
of anti-annexin-V conjugated to Brilliant Violet 421 (640923, Biolegend) was added to the
sample and incubated in the dark for 15 minutes. Single colour and unstained live and dead
cell populations were processed as well. Samples were then diluted with 1 mL of 5% FBS in
PBS and centrifuged at 500 x g. The volume was reduced to approximately 200 µL by
vacuum aspiration and 4 µL of 7-AAD solution (420404, Biolegend) was added prior to
analysis on a Becton Dickinson FACSCanto cytometer using FACSDiva software, acquiring
10,000 cell events per sample. Data generated were analyzed using FLOWJo software v10.2
(FLOWJo, LLC, Ashland, Oregon), gating populations according to forward and side scatter
profiles and setting live and dead specific populations according to positive control
populations and single colour stains.
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4.5

Supplemental

Supplemental Figure 4.1 CX-4945 and Inhibitor VIII Stimulate ERK1/2
Phosphorylation
HeLa cells were serum starved for 18 hours prior to treatment with EGF, CX-4945, Inhibitor
VIII or DMSO at indicated concentrations for 10 minutes.
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Supplemental Figure 4.2 Cell Viability of HeLa Cells Treated with CX-4945 and
Inhibitor VIII
HeLa cells were grown in media supplemented with FBS, followed by treatment with CX4945, Inhibitor VIII, Torin1 or staurosporine for 4 or 22 hours. Cells were processed for cell
viability analysis by flow cytometry, staining with 7-AAD, and an antibody against annexinV conjugated to BV-421. Non-viable cells are located in quadrant Q2.
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Supplemental Figure 4.3 Cell Viability of HeLa Cells Treated with DMSO
HeLa cells were grown in media supplemented with FBS, followed by treatment with DMSO
for 22 hours. Cells were processed for cell viability analysis by flow cytometry, staining
with 7-AAD, and an antibody against annexin-V conjugated to BV-421.
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Supplemental Figure 4.4 HeLa Cells Arrested in Specific Phases of Cell Cycle
HeLa cells were treated with lovastatin, mimosine, thymidine or nocodazole for 24 hours.
Cells were processed for cell cycle analysis by flow cytometry, staining with 7-AAD, and
antibodies against Ki-67 and phospho-histone H3 Ser10, both conjugated to AlexaFluor-488.
Gating was performed on forward and side scatter profiles to isolate single cells.
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Supplemental Figure 4.5 Chemical Structures of Multiplexed Inhibitor Beads
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5
5.1

Chapter 5 – Discussion
Introduction
The phosphorylation of proteins at serine, threonine and tyrosine residues is a critical

post-translational modification involved in the transmission of regulatory signals that control
cellular homeostasis. The addition of phosphate to these phospho-acceptor amino acid
residues is mediated by protein kinases in eukaryotes. Expectedly, deregulation of kinase
activity can contribute to aberrant signaling processes implicating kinases in the progression
of diseases such as cancer (8). The work presented in this thesis has been focused on protein
kinase CK2, a small family of enzymes that has been traditionally classified as
serine/threonine specific but also demonstrated to be capable of phosphorylating tyrosine
residues (209). Considering the number of proteins that are phosphorylated by CK2
implicating it in the regulation of several pathways (15), and its deregulated expression in
several different types of human cancer (14), CK2 has emerged as a therapeutic target. In
fact, an orally bioavailable small molecule ATP-competitive inhibitor of CK2, CX-4945, has
recently progressed into clinical trial (44). Given the emergence of CK2 as a therapeutic
target, the goal of this thesis was to utilize a mass-spectrometry based proteomics approach
to perform unbiased profiling of CX-4945. This approach enabled the identification of
dynamic markers of CK2 inhibition and CK2-dependent processes in cells treated with CX4945, as well as revealing potential CK2-independent effects of CX-4945.
5.2

Summary of Research Contributions

5.2.1 Development of a Phosphoproteomic Workflow
Prior to directly undertaking a phosphoproteomics approach to characterize the
effects of CX-4945 in HeLa cells, a comparative investigation of sample preparation methods
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was performed in order to determine an optimized phosphoproteomics workflow.
Conventional phopshoproteomic strategies typically take advantage of large-scale
fractionation methods such as strong-cation exchange chromatography to increase the
enrichment of lower abundance phosphopeptides (96). With recent advances in mass
spectrometry, strategies for phosphopeptide enrichment that do not require fractionation have
also been developed and have been documented to perform comparably to fractionation
approaches such as strong cation exchange chromatography (108). In chapter 2, comparison
of strategies for phosphopeptide enrichment performed both with and without fractionation
by strong cation exchange demonstrated that the two approaches were comparable in
phosphopeptide identification. By comparing different sorbents for sample desalting, I
observed that using porous graphitic carbon for sample desalting resulted in an enrichment of
phosphopeptides that contained a CK2 consensus motif. Considering that the amino acid
specificity determinants for CK2 can render a peptide sequence hydrophilic in nature (9295), matching a sorbent such as porous graphitic carbon which is selective for polar
compounds enables better identification of CK2 phosphopeptides than using a reverse-phase
C18 sorbent. Another recent development in a phosphopeptide enrichment protocol termed
“EasyPhos” utilizes a digestion buffer compatible with phosphopeptide enrichment thereby
omitting desalting prior to enrichment, and takes advantage of mixed-mode styrene-divinylbenzene reverse phase sulfonate sorbent (SDB-RPS) for desalting prior to LC-MS/MS
analysis (210). This results in a simplified format omitting steps which can incur sample loss
normally observed with desalting, reducing the amount of protein sample required for
enrichment and enabling the retention of hydrophilic phosphopeptides for LC-MS/MS.
Considerations in tailoring sorbents and protocols for enrichment of target analyte can
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enhance contextual biological information in proteomic investigations of interest. The
comparison of porous graphitic carbon to C18 solid phase extraction columns for peptide
desalting demonstrates the utility of hydrophilic sorbent in analyzing phosphopeptides
derived from CK2 substrates.
The investigation of proteome preparation revealed advantages in using protein
precipitation in comparison to filter-aided sample preparation for the generation of proteomes
for subsequent phosphopeptide enrichment. Although both preparation methods identified
nearly the same number of proteins, protein precipitation yielded more phosphorylation sites.
In this thesis protein precipitation was performed using TCA and acetone overnight at -20
°C. However other protein precipitation protocols such as chloroform/methanol (211) which
can be done within the span of one hour could be used in order to reduce sample processing
time.
In summary, when considering the evaluation of CK2 phosphopeptides by mass
spectrometry it is necessary to tailor sorbents and materials to match the unique determinants
that render the substrates of CK2 hydrophilic. It was demonstrated that using porous
graphitic carbon could enrich for phosphopeptides conforming to the CK2 consensus
sequence. In considering the practical aspects of profiling the phosphoproteome, sample
handling and instrument time are reduced when utilizing an unfractionated strategy. This
resulted in similar rates of protein and phosphorylation site identification. Furthermore,
comparative analysis of proteome sample preparation strategies identified that protein
precipitation of samples coupled with two-step C18 and porous graphitic carbon peptide
desalting in combination with phosphopeptide enrichment enables the identification of a
maximum number of proteins and phosphorylation sites in a timely manner. Taken together,
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these results demonstrate the utility of an unfractionated phosphoproteomics tailored with
hydrophilic sorbents that should be employed when analyzing CK2 phosphopeptides.
5.3

Unbiased Proteomic Characterization of CX-4945

5.3.1 CX-4945 Results in a Dynamic Phosphoproteome
CX-4945 represents the first clinical stage ATP-competitive inhibitor of CK2 to
progress into clinical trial. Despite the advances of CX-4945 in therapeutic applications and
widespread utilization as the “gold standard” CK2 inhibitor in the research community, it is
unclear how its effects are rendered in cells. A systematic quantitative phosphoproteomic
approach was undertaken utilizing SILAC labeled cells to characterize the impact of CX4945 treatment in HeLa cells following the optimization of a phosphoproteomics workflow
tailored to identify phosphopeptides derived from CK2 substrates. This approach enabled the
identification of phosphorylation sites indicating CK2 inhibition that exhibited dynamic dephosphorylation over a period of 240 minutes. Several of these sites displayed a magnitude
of change that was greater than that of EIF2S2 Ser2, a bona fide substrate of CK2 that has
been previously exploited to monitor CK2 inhibition in cells. This included the identification
of topo-isomerase II alpha (TOP2A) Ser1377 and presents an opportunity to use this
phosphorylation site as an indicator of CK2 inhibition in cells. Furthermore, identification of
differential de-phosphorylation on EIF2S2 at Ser2 and Thr111 in response to CX-4945
highlights a previously underappreciated role of phosphatase activity towards CK2
phosphorylation sites on the same protein.
Overall, analysis of CK2 phosphorylation sites that decreased in response to CX-4945
utilizing gene set enrichment analysis identified biological processes involved in DNA repair
and translation. Previous studies have also highlighted the role that CK2 plays in regulating
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proteins that are components of these processes (29, 212). Collectively, these findings
suggest that these biological processes may be representative of the most critical pathways
involved in the maintenance of cellular homeostasis that are first affected upon inhibition of
CK2.
The phosphoproteomics approach presented in chapter 3 also enabled the profiling of
phosphorylation sites attributed to other kinases that were revealed using kinase substrate
enrichment analysis. Inhibition of CK2 may lead to the indirect regulation of other kinases in
the cell. There is precedence for the regulation of kinases through the activity of CK2
towards the phosphorylation of cdc37 Ser13, a kinase co-chaperone (136). Interestingly,
treatment with CX-4945 within the period of time up to 240 minutes affected several other
kinases such as Akt1 and mTOR as concluded by the phosphorylation status of target
substrates.
MIB profiling was performed in order to investigate whether changes observed in the
phosphoproteomic profiling would correlate with the change in activity of the respective
upstream kinases. Indeed when this investigation was followed up, kinases in the
PI3K/Akt/mTOR pathways were affected by CX-4945. Although the quantification of
activity in mTOR did not change drastically as well as CK2, other kinases that are
downstream of mTOR such as Akt1, Sgk1 and Ulk1 changed in activity suggesting mTOR
inhibition.
5.3.2 Limitations of Profiling Effects of CX-4945 in HeLa Cells Using MIBs
One potential limitation in using MIBs to determine the activity of kinases that are
targets of CX-4945 in cells is that the residual amount of CX-4945 in the lysate that could
interfere with the ability of kinases to bind to the MIBs. Considering that the protein extracts
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from treated and untreated samples are mixed 1:1 prior to MIB profiling, residual CX-4945
from the treated samples may interfere with the CK2 catalytic subunits derived from cells
that were treated with DMSO. Consequently, this may also impact the putative off-targets of
CX-4945, thus explaining why regulation of mTOR was not apparent although downstream
targets were quantified.
Another limitation may relate to the composition of the inhibitor mix used for profiling.
In this respect, a recent investigation of kinase activity profiling methods such as MIBs
identified cases where capture of kinases by MIBs was independent of kinase activity (213).
The MIB strategy by Duncan et al. (84) is intended to isolate the active kinome. Ruprecht et
al. (214) noted that the type inhibitor mix used could affect the conformation-dependent
binding. On a related note, determining which variable modifications are included for
peptides derived from kinases that are used for quantification may also obscure the activity of
a kinase by MIB profiling. Typically peptides with variable modifications that could play a
regulatory role are excluded in the quantitation at the protein level, and only modifications
that result because of sample handling, as in the case of methionine oxidation are included in
such searches. This was the case for ERK1/2 where the quantification at the protein level
revealed no apparent change but the phosphorylation status of Thr202/Tyr204 and
Thr185/Tyr187 increased. In these analyses, peptides with phosphorylation as a variable
modification were excluded in the calculation of protein abundance considering it was
unknown beforehand whether phosphorylation sites on kinases which change but do not
confer activation status could result in quantification unrepresentative of biochemical
function. Despite this limitation, utilizing the phosphorylation specific data collected in these
experiments still enabled investigation of kinase activity. Efforts to overcome the limitations
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of affinity-capture strategies, such as MIBs for profiling the active kinome, represent an
active area of investigation. In this respect, a very recent study presented an optimized MIB
mix using 12 different inhibitors that when coupled with improvements in liquid
chromatography using monolithic columns and targeted mass spectrometry enabled the
reliable quantification of active kinases (215). Looking to the future, it can be expected that
further technological developments in this field will improve the systematic quantification of
kinase activity by MIB profiling.
5.3.3 Differential Effects of CX-4945 and Inhibitor VIII in HeLa cells
The phosphoproteomic and kinome profiling suggested that mTOR was also affected in
addition to inhibition of CK2. By comparison, treatment of HeLa cells with an unrelated
inhibitor, “Inhibitor VIII” identified a differential effect upon the PI3K/Akt/mTOR pathway
in contrast to CX-4945, with both inhibitors displaying a decrease in phosphorylation of
EIF2S2 Ser2. This result suggests that CX-4945 is also a putative inhibitor of mTOR in
HeLa cells and warrants further investigation. This contrasted to the observation that both
Inhibitor VIII and CX-4945 treatment resulted in activation of the ERK MAPK pathway.
Interestingly, when cell cycle analysis was performed by flow cytometry, CX-4945 and
Inhibitor VIII treatment also resulted in distinct effects on phospho-histone H3 Ser10.
Collectively, these results raise questions about the specificity of these CK2 inhibitors and
emphasize the need for systematic characterization of kinase inhibitors to both validate
inhibition of the intended target and identify potential downstream effects of target inhibition
or potential off-targets. Furthermore, the results presented in this thesis highlight the
underappreciated complexity of the phosphoproteome when challenged with CX-4945,
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which has been used extensively as the “gold standard” CK2 inhibitor given its emergence in
ongoing clinical trial.
5.4

Future Directions

5.4.1 Characterization of CK2-independent Effects of CX-4945 in cells
Given the utility of small molecule inhibitors in delineating signaling pathways in cells, it is
critical to understand the potential off-target effects that may incorrectly attribute protein
function to a pathway. The identification of the PI3K/Akt/mTOR pathway as a putative target
of CX-4945 raises questions about the precise mechanisms of action of CX-4945 in cells.
There is previous literature which suggests that CX-4945 can down-regulate the
PI3K/Akt/mTOR pathway (51, 54, 189): however, in this thesis comparative investigation
using another unrelated CK2 inhibitor revealed differential effects on this pathway. In
particular, treatment with CX-4945 and Inhibitor VIII displayed differences in the
phosphorylation of 4E-BP1, although both inhibitors decreased the phosphorylation of
EIF2S2 Ser2. The phosphorylation status of substrates of kinases is one approach that has
been utilized to understand drug-target engagement in cells but is considered an indirect
read-out. A recent study proposed an innovative assay as an alternative strategy in drug
discovery to examine drug-target engagement in cells, cell extracts and tissues. The cellular
thermal shift assay (CETSA) relies on the biophysical concept of ligand-induced thermal
stabilization of proteins and enables the assessment of drug binding to a protein (216). By
incubating aliquots of cell lysate with a drug and subjecting each aliquot to a different
temperature, the amount of the target protein of interest that remains soluble can be measured
and a thermal melt curve can be calculated. Stabilization of the target protein by the drug will
result in a shifted melt curve, and can be used to identify drug-target protein interaction. This
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application can be adapted for western blotting or in micro-titer plates for increased
throughput (217). Recent developments in mass spectrometry technology coupled with
tandem mass tag labeling reagents have also enabled the monitoring of several thousand
proteins and the respective melt curves in response to inhibitor treatment (218).

This

analysis identified ferrochelatase as a novel target of vemurafenib and alectinib, highlighting
a previously unreported mechanism of action that explains known photosensitivity side
effects. Although the application of thermal proteome profiling by mass spectrometry
requires the use of specific mass spectrometry instrumentation and reagents, it would be
feasible on a smaller scale to begin to study the effect of CX-4945 on constituents of the
PI3K/Akt/mTOR pathway by utilizing protein specific antibodies in an adaption of CETSA
for western blotting.
5.4.2 Investigating the CK2-dependent Phosphoproteome Using Cells Engineered to
express CX-4945-resistant CK2
The phosphoproteomics workflow investigating the effect of CX-4945 treatment on HeLa
cells presented in this thesis identified its broad impact on the phosphoproteome. Considering
that CX-4945 treatment resulted in the regulation of several different kinases, it would be of
interest to be able to delineate which of the signaling events observed are indirect effects of
CK2 inhibition as opposed to off-targets. Another factor in the CK2 field that has been
underappreciated is the ability to discriminate between the isoform specificity of CK2α and
CK2α phosphorylation, as CX-4945 can inhibit both isoforms (44). In an effort to understand
the structural basis of CK2 inhibition by ATP-competitive inhibitors, previous studies have
identified critical residues in the ATP-binding pocket of CK2α, including Val66 and Ile174
that are essential for inhibitor binding. Furthermore, mutation of these residues to alanine

157
resulted in resistance to binding with a number of CK2 inhibitors while retaining catalytic
activity (219). In the case of CX-4945, structural studies have also revealed an important
role of His160 for interactions between CK2α and CX-4945 (or His161 in the case of
CK2α’). Increased resistance to treatment with CX-4945 is achieved by substituting His160
(or His161) to glutamic acid or aspartic acid in combination with Val66Ala/Ile174/Ala
substitutions. These studies have inspired efforts in our laboratory to devise chemical
proteomic strategies to investigate cellular targets of CK2 inhibitors (18). In addition, this
information has also been exploited to generate cell lines harboring inhibitor-resistant forms
of CK2α and CK2α’, that are dramatically less sensitive to a number of CK2 inhibitors
including CX-4945 and Inhibitor VIII treatment.
The work that is described in this thesis utilized duplex SILAC to enable relative
quantification of peptides derived from CX-4945 treated cells versus control cells. This
approach utilized labeling one set of cells with arginine (13C6) and lysine (4,4,5,5-d4)
resulting in mass shifts of 6 and 4 Da respectively in comparison to normal isotope encoded
amino acids. To extend these studies, triplex SILAC-based phosphoproteomics can be
employed using the cell lines harboring inhibitor resistant forms of CK2 to distinguish
between direct and indirect CK2 signaling events as well as characterizing off-target effects
(Figure 5.1). Utilizing a third set of labeled arginine (13C6 15N4) and lysine (13C6 15N2) which
would result in mass shifts of 10 and 8 Da respectively, a population of inhibitor-resistant
cells treated with CX-4945 could be compared to DMSO and CX-4945 wild-type treated
cells, enabling the identification of phosphopeptides that are affected by the inhibitor in the
presence of the inhibitor-resistant forms of CK2. Furthermore, comparison of datasets
obtained from inhibitor-resistant CK2α and CK2α’ cells could identify sets of
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phosphorylation sites that are differentially regulated, indicating isoform-specific substrates.
Related experiments utilizing a triplex SILAC approach could also take advantage of
different classes of CK2 inhibitors, such as those that target unique features outside of the
ATP-binding pocket (220) or which abrogate the stability of the tetrameric holo-enzyme
complex of CK2 (221). This would enable the identification of phosphorylation sites on
substrates that require tetrameric CK2. Overall, the development of inhibitor-resistant cell
lines presents interesting opportunities for studying CK2-dependent signaling events under
different biological contexts and will greatly aid in the characterization of cellular processes
regulated by CK2.
5.4.3 Targeted Profiling of CK2-dependent Phosphoproteome Using Mass
Spectrometry
The identification of phosphorylation sites that display dynamic de-phosphorylation
in response to CX-4945 will serve as a useful panel of activity markers upon which a targeted
strategy to monitor the actions of CX-4945 can be developed. As these phosphorylation sites
are derived from phosphopeptides that were detected using data-dependent acquisition
methods, the likelihood of successfully developing a targeted mass spectrometry assay to
profile CK2 activity is high (222). Historically, selected reaction monitoring (SRM) (also
referred to as multiple reaction monitoring (MRM)) has been used as the gold standard for
profiling proteotypic peptides (223). Further advances in mass spectrometry instrumentation
have enabled the utilization of a similar technique termed parallel reaction monitoring (PRM)
that can be performed on hybrid quadrupole-orbitrap instruments, such as the Q Exactive
(224, 225). The advantage of PRM lies within the ability to simultaneously monitor all
fragment ions from a precursor ion selected in MS1 with high resolution and high mass
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accuracy in comparison to SRM, and does not require a priori optimization of precursor and
fragment ion transitions. A recent application of a targeted PRM assay demonstrated the
utility of using a panel of isotopically-labeled synthetic phosphopeptides as a readout for a
phosphorylation signature that could be used to monitor the effect of different chemical
inhibitors (226). PRM assays could also be used to monitor the activity of individual kinases
in particular contexts. In this respect, proteomic investigations have identified CK2
phosphorylation sites that increase in response to stimuli such as DNA damage (35, 36),
metformin (227), and vemurafenib (85) that could be monitored using PRM strategies.
Therefore, synthesis of isotopically-labeled phosphopeptides that are representative of CK2
activity could be used to systemically profile CK2 activity using a PRM assay in cells treated
with DNA damaging agents or potentially in different biological contexts. Considering the
therapeutic potential of CK2 as a clinically relevant target, a panel of targeted
phosphopeptides could be used to profile samples derived from patient tissues receiving CX4945 to assess treatment efficacy or efficacy of new CK2 inhibitors as they emerge in the
literature.
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Figure 5.1 Comparative Phosphoproteomic Analysis Using Inhibitor-Resistant Cells to
Identify Bona Fide Effects of CK2 and Bona Fide CK2-independent Effects of CX-4945.
Cells harboring inhibitor-resistant forms of CK2 treated with CX-4945 can be compared
directly to wild-type cells in a triplex SILAC approach. Quantification of phosphopeptides
representing bona fide CK2 substrates or CK2-dependent phosphorylation sites will remain
comparable in abundance between wild-type cells (WT) treated with DMSO and inhibitorresistant cells (IR) treated with CX-4945. Bona fide CK2-independent effects of CX-4945
will be discernable as quantification of these phosphopeptides will differ between DMSO
treated wild-type cells and CX-4945 treated inhibitor resistant cells.
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5.5

Conclusion
The dynamic nature of protein phosphorylation as mediated by the activity of kinases

and phosphatases renders it a critical posttranslational modification in the regulation of
biological processes. The emergence of protein kinase CK2 as a therapeutic target has been
met with the development of several inhibitors including CX-4945, a small molecule ATPcompetitive inhibitor that has progressed into clinical trial. Furthermore, CX-4945 has been
used widely in the literature in different models of cancer but these reports are anecdotal in
terms of the specific signaling pathways that were studied in isolated biological contexts.
Unbiased proteomic characterization of the effect of CX-4945 in human cells was undertaken
in order to understand the scope of its impact on the phosphoproteome and the kinome. These
studies enabled the identification of markers of CK2 activity, which can have applications for
characterizing future CK2 inhibitors and also identified putative CK2-independent effects of
CX-4945. The identification of CK2-independent effects raises speculation about the
mechanism of action of CX-4945 in cells and highlights the need within the CK2 research
community and the larger kinome research community for well-characterized chemical
probes and complementary model systems in which to test hypotheses.
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